Note: Descriptions are shown in the official language in which they were submitted.
CA 02979840 2017-09-14
WO 2016/149460 PCT/US2016/022787
IMMUNOGENIC COMPOSITIONS AND VACCINES FOR PREVENTING OR
TREATING FILARIAL DISEASE
CROSS REFERENCE TO RELATED APPLICATIONS
[001] This application claims the benefit of, and relies on the filing date
of, U.S. provisional
patent application number 62/135,115, filed 18 March 2015, the entire
disclosure of which is
incorporated herein by reference.
STATEMENT OF GOVERNMENT INTEREST
[002] The present invention arose in part from research funded by grant R073UE
from the
Uniformed Services University of the Health Sciences. The U.S. Government may
have
certain rights in this invention.
SEQUENCE LISTING
[003] The instant application contains a Sequence Listing which has been
submitted
electronically in ASCII format and is hereby incorporated by reference in its
entirety. Said
ASCII copy, created on March 9, 2016, is named HMJ-150-PCT 5T25.txt and is
120,000
bytes in size.
BACKGROUND
[004] The filariae are thread-like parasitic nematodes (roundworms) that are
transmitted by
arthropod vectors. The adult worms inhabit specific tissues where they mate
and produce
microfilariae, the characteristic tiny, thread-like larvae.
[005] The microfilariae infect vector arthropods, in which they mature to
infective larvae.
Diseases caused by filariae are a major health problem in many tropical and
subtropical areas.
Wuchereria bancrofti and Brugia malayi are filarial parasites that are the
major causative
agents of lymphatic filariasis. Currently, it is estimated that over 129
million people are
infected with either of these organisms and over one billion live in at-risk
areas. Since 2000,
there has been an ongoing effort through the Global Program to Eliminate
Lymphatic
Filariasis to eradicate these infections. While this program is having a
substantive impact on
the prevalence of infection, its efficacy is limited by the need to repeatedly
treat entire
endemic populations for 6-10 years. The advent of new tools, such as vaccines
or more
effective anthelmintics, would be of great benefit toward these eradication
efforts.
CA 02979840 2017-09-14
WO 2016/149460 PCT/US2016/022787
[006] ] One of the principle obstacles in designing vaccines against such
parasitic worms,
however, is that previously exposed individuals frequently have IgE antibodies
to surface and
secreted worm antigens, putting them at risk for allergic reactions when re-
exposed to these
antigens. Since intestinal antigens of helminths may be "hidden" from the
immune response
during natural infection, yet accessible by antibodies after antigen
administration,
homogenates of such antigens have been proposed for use in vaccines. However,
while the
genomes of Wuchereria bancrofti and Brugia malayi, as well as the filarial
genomes of the
causative agents of loiasis and river blindness have been completed, the
anatomic localization
of proteins in these filarial worms is unknown. Moreover, the use of
homogenates from
helminth intestines has resulted in variable efficacy.
[007] Other diseases known in the art, which are caused by filarial parasites,
include
heartworm disease. This disease is caused by the parasite Dirofilaria immitis.
The physical
presence of the heartworm parasite in the pulmonary artery and right ventricle
of the canine
heart, for example, and the resulting destruction of tissue, causes
respiratory and circulatory
problems which can be fatal under conditions of stress or vigorous exercise.
The heartworm
parasite has also been shown to be the cause of focal lung, liver, eye and
cutaneous lesions in
man. Currently, heartworm disease is treated by administering anti-parasitic
agents to
infected animals. Unfortunately, heartworm disease that has not been diagnosed
in its early
stages may be quite refractile to treatment.
[008] Accordingly, there is a need in the art for immunogenic compositions,
such as vaccines,
which may be used to prevent or treat diseases caused by filarial worms
including lymphatic
filariasis, loiasis, river blindness and heartworm.
BRIEF SUMMARY
[009] Further areas of applicability of the present disclosure will become
apparent from the
detailed description provided hereinafter. It
should be understood that the detailed
description and specific examples, while indicating embodiments of the
disclosure, are
intended for purposes of illustration only and are not intended to limit the
scope of the
disclosure.
[0010] The present disclosure is directed to an immunogenic composition
including: at least
one or at least two isolated polypeptides or immunogenic fragments thereof,
and optionally a
pharmaceutically acceptable carrier, wherein each polypeptide is expressed on
a luminal
surface of an intestine of a filarial worm, wherein each polypeptide is
expressed at a level at
least two-fold higher in the intestine in comparison to the level of
expression of each
2
CA 02979840 2017-09-14
WO 2016/149460 PCT/US2016/022787
polypeptide in a reproductive tract or a body wall of the filarial worm,
wherein each isolated
polypeptide has at least one transmembrane domain, and wherein each
polypeptide is a non-
mitochondrial polypeptide.
[0011] Also provided herein is a method for preventing or treating a filarial
disease including
administering an effective amount of a vaccine composition including at least
one or at least
two isolated polypeptides or immunogenic fragments thereof to a subject in
need thereof,
wherein each polypeptide is expressed on a luminal surface of an intestine of
a filarial worm,
wherein each polypeptide is expressed at a level at least two-fold higher in
the intestine in
comparison to the level of expression of each polypeptide in a reproductive
tract or a body
wall of the filarial worm, wherein each isolated polypeptide has at least one
transmembrane
domain, and wherein each polypeptide is a non-mitochondrial polypeptide.
BRIEF DESCRIPTION OF THE DRAWINGS
[0012] The present disclosure will become more fully understood from the
detailed
description and the accompanying drawings, wherein:
[0013] [FIG. 1 depicts the anatomy of adult female B. malayi. The tissues and
structures
dissected for the proteomic analysis as described in the Examples include the
body wall,
reproductive tract and intestine.
[0014] FIGS. 2A and 2B depict the dissection process of adult female B.
malayi. FIG. 2A
shows a break in the body wall and extrusion of the gut and reproductive tract
as described in
the Examples. Magnification: top left: 40x, bottom left: 100x. FIG. 2B shows
the body wall
in the process of being slid away from the gut and reproductive tract.
Magnification: top
right: 30x, bottom right: 20x.
[0015] FIG. 3A depicts a Venn diagram of proteins identified within each
anatomic fraction
of adult female Brugia malayi based on a 2 peptide minimum for identification
as described
in the Examples.
[0016] FIG. 3B depicts a heat map of hierarchical clustered proteins found
within the
different anatomic fractions of adult female B. malayi.
[0017] FIG. 4 depicts the association of transporter proteins with the
intestine as measured by
gene set enrichment analysis (GSEA) P-value=0.005, as described in the
Examples.
[0018] FIG. 5A depicts the association of immunological (P-value=0.003)
proteins with the
body wall of the adult female B. malayi as measured by GSEA, as described in
the Examples.
3
CA 02979840 2017-09-14
WO 2016/149460 PCT/US2016/022787
[0019] FIG. 5B depicts the association of cytoskeletal proteins (P-value=0
0.009) with the
body wall of the adult female B. malayi as measured by GSEA, as described in
the Examples.
[0020] FIG. 6A depicts the association of transcription (P<0.001with the
reproductive tract of
adult female B. malayi as described in the Examples.
[0021] FIG. 6B depicts the association of nuclear regulation proteins
(P=0.013) with the
reproductive tract of adult female B. malayi as described in the Examples.
DETAILED DESCRIPTION
[0022] The following description of the embodiments is merely exemplary in
nature and is in
no way intended to limit the disclosure, its application, or uses.
[0023] As used throughout, ranges are used as shorthand for describing each
and every value
that is within the range. Any value within the range can be selected as the
terminus of the
range. In addition, all references cited herein are hereby incorporated by
reference in their
entireties. In the event of a conflict in a definition in the present
disclosure and that of a cited
reference, the present disclosure controls.
[0024] Unless otherwise specified, all percentages and amounts expressed
herein and
elsewhere in the specification should be understood to refer to percentages by
weight. The
amounts given are based on the active weight of the material.
Immunogenic Composition
[0025] In some embodiments, the present disclosure encompasses an immunogenic
composition comprising at least one isolated polypeptide as described herein
or an
immunogenic fragment thereof and optionally a pharmaceutically acceptable
carrier.
[0026] The term "polypeptide" as used herein refers to a polymer of amino acid
residues.
This term is used interchangeably with the term "protein."
[0027] In some embodiments, the present polypeptides are obtained or derived
from a filarial
worm. A "filarial worm" as used herein refers to parasitic nematodes of the
Metazoa
kingdom including the superfamily filarioidea, family Filariidae. Filarial
worms include, but
are not limited to, species belonging to the genera Brugia, such Brugia
malyai, Wuchereria,
such as Wuchereria bancrofti, Onchocerca, such as Onchocerca volvulus, Loa,
such as Loa
loa and Dirofilaria, such as Dirofilaria immitis. The phrase "derived from"
encompasses
actually or theoretically "originating from," "obtained from," or "isolated
from" a parent
polypeptide.
4
CA 02979840 2017-09-14
WO 2016/149460 PCT/US2016/022787
[0028] In some embodiments, the polypeptides of the present immunogenic are
expressed on
a luminal surface of a filarial worm intestine. Without being bound by theory,
it is believed
that administering such intestinal luminal surface polypeptides to a subject
may mitigate the
possibility of an allergic reaction in the subject. Because intestinal
antigens may be "hidden"
from the immune response during natural infection, yet accessible by
antibodies induced by
administration, intestinal antigens are likely to have a low potential for
eliciting allergic
responses when administering, such as vaccinating, previously infected
individuals. Further,
it is believed that administering, such as vaccinating, a subject with
particular intestinal
antigens, such as the polypeptides or immunogenic fragments thereof described
herein, may
be more effective than vaccinating with crude homogenates of antigens since,
for example,
sufficient amounts of effective antigen may not be present in such mixtures.
Accordingly, in
some embodiments, the present immunogenic composition consists essentially of
the isolated
polypeptides disclosed herein, such as one or more isolated polypeptides
selected from SEQ
ID NOS: 1-27 or immunogenic fragments thereof and a pharmaceutically
acceptable carrier
and does not encompass crude homogenates of antigen, such as a crude
homogenate of
intestinal proteins.
[0029] In various embodiments, the present polypeptides are enriched in the
intestine of a
filarial worm in comparison to another anatomic fraction of a filarial worm.
As used herein,
"enriched" or "abundant" refers to a polypeptide that is naturally found to be
expressed at a
higher level in the intestine, for example, in comparison to other anatomic
fractions, such as
the reproductive tract or the body wall. See FIG. 1, which depicts the anatomy
of a filarial
worm. In some embodiments, the expression level of the polypeptide is at least
two fold
higher, such as at least three fold higher, such as at least five fold higher,
such as at least 10
fold higher, such as at least 50 fold higher in the intestine in comparison to
the expression
level of the polypeptide in the reproductive tract or the body wall of the
filarial worm.
[0030] Enrichment or abundance of polypeptides can be assessed by any method
known in
the art. For example, protein separation and comparison by two-dimensional
polyacrylamide
gel electrophoresis (2D-PAGE), followed by mass spectrometry (MS) or tandem
mass
spectrometry (MS/MS) identification may be used for quantitative analysis of
protein
mixtures, see, for example, H. J. Issaq and T. D. Veenstra, BioTechniques,
vol. 44, no. 5, pp.
697-700, 2008, which is herein incorporated by reference. In this method, the
intensity of
the protein stain is used to make a determination regarding the quantity of a
particular
protein.
CA 02979840 2017-09-14
WO 2016/149460 PCT/US2016/022787
[0031] Protein quantitation may also be assessed using non-gel-based "shotgun"
proteomic
techniques such as Multidimensional Protein Identification (MudPIT). See e.g.,
A.
Motoyama and J. R. Yates III, Analytical Chemistry, vol. 80, no. 19, pp. 7187-
7193, 2008
and B. Domon and R. Aebersold, Science, vol. 312, no. 5771, pp. 212-217, 2006,
which are
each herein incorporated by reference.
[0032] Non-gel based proteomic methods may include (i) sample preparation
including
protein extraction, reduction, alkylation, and digestion; (ii) sample
separation by liquid
chromatography (LC or LC/LC) and analysis by MS/MS; (iii) data analysis
including
peptide/protein identification, quantification, and statistical analysis. For
example, each
sample may be separately prepared, then subjected to individual LC-MS/MS or
LC/LC-
MS/MS runs. Protein abundance may be assessed, for example, using spectral
counting of
identified proteins after MS/MS analysis. Spectral count may be measured for
individual LC-
MS/MS or LC/LC-MS/MS runs and changes in protein abundance may be calculated
via a
direct comparison between different analyses.
[0033] Typically, normalization and statistical analysis of spectral counting
datasets are used
to detect changes in protein abundance in complex mixtures. See, for example,
McIlwain et
al., 2012, BMC Bioinformatics, 13, 308, Paoletti et al., 2006, Proc. Natl.
Acad. Sci. U. S. A.,
103, 18928-18933, regarding determining the relative abundance of a single
protein between
samples and Liu et al., 2004, Anal. Chem.,76, 4193-4201, for example,
regarding estimating
relative abundance between different proteins in one sample. These references
are herein
incorporated in their entireties.
[0034] The relative abundance of the present polypeptides may be assessed
using
normalization and statistical analysis of spectral counting datasets as
described in the present
Examples. For example, Normalized Spectral Abundance Factor (NSAF) and NSAF
enrichment values may be determined (see Examples). In some embodiments, the
polypeptides of the present disclosure exhibit an NSAF enrichment value of at
least 2, such as
at least 3, such as at least 4, such as at least 20 in the intestine and less
than 2, such as less
than 1 or less than 0.5 in other atomic fractions, such as the body wall or
the reproductive
tract.
[0035] In some embodiments, the polypeptides of the present immunogenic
composition
have at least one transmembrane domain, such as 1-2 transmembrane domains, to
facilitate
recombinant expression and a non-cytoplasmic portion to increase the
likelihood of
interaction with antibodies ingested by filariae. The non-cytoplasmic portion
may be for
example, 50 amino acids in length or more, such as 100 amino acids in length
or more, such
6
CA 02979840 2017-09-14
WO 2016/149460 PCT/US2016/022787
as 500 amino acids in length or more. Such features may be determined using
methods
known in the art or predicted using art known software, e.g. Interpro, Zdobnov
EM, Apweiler
R. 2001. InterProScan-an integration platform for the signature-recognition
methods in
InterPro. Bioinformatics 17: 847-848, which is herein incorporated by
reference.
[0036] In some embodiments, the polypeptide of the present disclosure is
specific to the
intestine. "Specific" in reference to a particular anatomical fraction of the
worm means that
the polypeptide was only identified within the specific fraction, e.g., the
intestine.
[0037] In some embodiments, the present polypeptides are non-mitochondrial
peptides, i.e.
not present, targeted to or expressed in the mitochondria.
[0038] As noted above, the present composition comprising at least one
isolated polypeptide
is an immunogenic composition. As used herein, the term "immunogen" or
"immunogenic"
refers to any substrate that elicits an immune response in a host, e.g., at
least an antibody
response. An "immunogenic composition" includes at least one isolated
polypeptide with or
without a pharmaceutically acceptable carrier, such as an adjuvant. The
immunogenic
compositions disclosed herein may or may not be immunoprotective or
therapeutic.
Accordingly, the term "immunogenic" is not intended to be limited to vaccines.
[0039] In some embodiments, the immunogenic composition of the present
disclosure is a
vaccine. As used herein, a vaccine encompasses an immunogenic composition that
prevents,
ameliorates, palliates, or eliminates disease from a host, such as the
diseases described herein.
[0040] In other embodiments, the immunogenic composition described herein may
be used to
obtain an antibody composition, which may then be administered to a subject to
provide
temporary immunity, i.e., artificially acquired passive immunity. Methods for
preparing and
administering such antibody compositions are known in the art and are
described, for
example, in U.S. 4,748,018, which is herein incorporated by reference in its
entirety.
[0041] As described herein, a polypeptide of the present immunogenic
composition is an
isolated polypeptide. The terms "isolated" or "purified" or "biologically
pure" refer to
material that is substantially or essentially free from components that
normally accompany it
as found in its native state. Purity and homogeneity are typically determined
using analytical
chemistry techniques such as polyacrylamide gel electrophoresis or high
performance liquid
chromatography. A protein that is the predominant species present in a
preparation is
considered to be substantially purified. The term "purified" denotes that a
protein gives rise
to essentially one band in an electrophoretic gel. For example, it means that
the protein is at
least 85% pure, such as at least 95% pure or at least 99% pure.
7
CA 02979840 2017-09-14
WO 2016/149460 PCT/US2016/022787
[0042] In some embodiments, the polypeptide of the present immunogenic
composition is a
polypeptide selected from SEQ ID NOS: 1-27. In some embodiments, the isolated
polypeptide is a cell adhesion protein, such as a polypeptide of SEQ ID NOS: 1
or 2. In some
embodiments, the isolated polypeptide is a cell signaling protein, such as a
polypeptide of
SEQ ID NOS: 3 or 4. In some embodiments, the polypeptide is a chaperone/HSP
protein,
such as a polypeptide of SEQ ID NOS: 5 or 6. In some embodiments, the
polypeptide is
involved in xenobiotic metabolism using glucuronidation, for example, a UDP-
glucuronosyl
or a UDP glucosyl transferase, such as a polypeptide of SEQ ID NOS: 7 or 8,
respectively.
In some embodiments, the isolated polypeptide is a protease such as SEQ ID
NOS: 13, 14 or
15. In some embodiments, the isolated polypeptide is a protease inhibitor,
such as SEQ ID
NO: 17. A description of SEQ ID NOS: 1-27 is found in Table 7 and Tables C and
D.
[0043] In some embodiments, the polypeptide of the present immunogenic
composition is an
immunogenic fragment, such as an immunogenic fragment of SEQ ID NOS: 1-27. The
phrase "immunogenic fragment" or "immunogenic portion" refers to a fragment or
truncated
form of an amino acid sequence, for example, an amino acid sequence selected
from the
group consisting of SEQ ID NOS. 1-27 that elicits an immunological response.
[0044] In some embodiments, the polypeptide of the present immunogenic
composition is an
immunogenic variant, such as an immunogenic variant of SEQ ID NOS: 1-27. The
phrase
"immunogenic variant" refers to a substituted form of an amino acid sequence,
for example,
an amino acid sequence selected from the group consisting of SEQ ID NOS. 1-27
that elicits
an immunological response. Insertions and/or deletions may also be
incorporated into an
immunogenic variant.
[0045] In some embodiments, the immunogenic variant of the present disclosure
comprises a
substitution, such as a conservative substitution for example, a substituted
form of an amino
acid sequence selected from the group consisting of SEQ ID NOS: 1-27
containing one or
more conservative amino acid substitutions. A "conservative amino acid
substitution" is one
in which the amino acid residue is replaced with an amino acid residue having
a side chain
with a similar charge. Families of amino acid residues having side chains with
similar
charges have been defined in the art. These families include amino acids with
basic side
chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic
acid, glutamic acid),
uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine,
threonine, tyrosine,
cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine,
proline,
phenylalanine, methionine, tryptophan), beta-branched side chains (e.g.,
threonine, valine,
isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine,
tryptophan, histidine).
8
CA 02979840 2017-09-14
WO 2016/149460 PCT/US2016/022787
[0046] In general, the immunogenic fragments and variants described herein,
such as
fragments or variants of the polypeptides of SEQ ID NOS: 1-27 comprise at
least one epitope
and include at least six contiguous amino acids from the full-length protein,
e.g., at least six
contiguous amino acids from the cell adhesion protein set forth in SEQ ID NO:
1. More
typically, the present variants or fragments will have at least 10, even more
typically at least
15, and still more typically at least 19, and yet even more typically 30
contiguous amino acids
from the full-length protein, e.g., the cell adhesion protein set forth in SEQ
ID NO: 1.
[0047] The term "epitope" means a segment or fragment of a composition of
matter, e.g., a
polypeptide, which is recognized by the immune system, specifically by
antibodies, B cells,
or T cells. In some embodiments, the epitope is generally a fragment or
fragments of a
polypeptide set forth in SEQ ID NOS: 1-27.
[0048] Such fragments can be identified using any number of epitope mapping
techniques,
well known in the art. See, e.g., Epitope Mapping Protocols in Methods in
Molecular
Biology, Vol. 66 (Glenn E. Morris, Ed., 1996) Humana Press, Totowa, NJ), which
is herein
incorporated by reference. For example, linear epitopes may be determined by
concurrently
synthesizing large numbers of peptides on solid supports, the peptides
corresponding to
portions of a protein molecule, and reacting the peptides with antibodies
while the peptides
are still attached to the supports. Such techniques are known and described in
the art, see
e.g., U.S. Pat. No. 4,708,871; Geysen et al., 1984, Proc. Natl. Acad. Sci.
U.S.A. 81,3998-
4002; and Geysen et al., 1986, Molec. Immunol. 23,709-715, which are herein
incorporated
by reference in their entireties. Similarly, conformational epitopes are
readily identified by
determining spatial conformation of amino acids, such as by, e.g., x-ray
crystallography and
two-dimensional nuclear magnetic resonance. See Epitope Mapping Protocols,
supra.
[0049] In some embodiments, the polypeptides of the present disclosure
encompass
polypeptides that are substantially homologous to the polypeptides set forth
in SEQ ID NOS:
1-27. The substantially homologous polypeptides may be from or derived from
any filarial
species or genera including but not limited to Brugia, such as Brugia malyai,
Wuchereria,
such as Wuchereria bancrofti, Onchocerca, such as Onchocerca volvulus, Loa,
such as Loa
loa and Dirofilaria, such as Dirofilaria immitis. In some embodiments, the
polypeptides of
the present disclosure, which are substantially homologous to the polypeptides
set forth in
SEQ ID NOS: 1-27 are not substantially homologous to a human polypeptide.
[0050] In some embodiments, the immunogenic composition includes at least one
isolated
polypeptide comprising an amino acid sequence selected from SEQ ID NOS: 1-7,
SEQ ID
9
CA 02979840 2017-09-14
WO 2016/149460 PCT/US2016/022787
NO: 11, SEQ ID NO: 14, SEQ ID NOS: 18-20, SEQ ID NO: 22, SEQ ID NO: 23 and SEQ
ID NO: 26.
[0051] In specific embodiments, the immunogenic composition includes at least
one, for
example, polypeptide obtained Dirofilaria immitis and displaying substantial
homology to a
polypeptide selected from SEQ ID NOS: 1-7, SEQ ID NO: 11, SEQ ID NO: 14, SEQ
ID
NOS: 18-20, SEQ ID NO: 22, SEQ ID NO: 23 and SEQ ID NO: 26.
[0052] As used herein, "homology" refers to the percent sequence identity
between two
polypeptide moieties. Two polypeptide sequences "display substantial homology"
or are
"substantially homologous" to each other when the sequences exhibit at least
about 41%,
such as at least about 75%, more typically at least about 80%-85%, even more
typically at
least about 90%, and most typically at least about 95%, 96%, 97%, 98%, 99% or
more
sequence identity over a defined length of the molecules. As used herein,
"substantially
homologous" also refers to sequences showing complete (100%) sequence identity
to the
polypeptide sequences.
[0053] In some embodiments, a sequence is not substantially homologous when it
exhibits a
sequence identity of 40% or less sequence identity.
[0054] "Sequence identity" as used herein refers to a relationship between two
or more
polypeptide sequences, namely a reference polypeptide sequence and a given
polypeptide
sequence to be compared with the reference polypeptide sequence. Sequence
identity is
determined by comparing the given polypeptide sequence to the reference
polypeptide
sequence after the polypeptide sequences have been optimally aligned to
produce the highest
degree of sequence similarity, as determined by the match between strings of
such sequences,
with gaps introduced if necessary. Upon such alignment, sequence identity is
ascertained on
a position-by-position basis, e.g., the sequences are "identical" at a
particular position if at
that position, the amino acid residues are identical. The total number of such
position
identities is then divided by the total number of residues in the reference
sequence to give %
sequence identity.
[0055] Sequence identity can be readily calculated by known methods, including
but not
limited to, those described in Computational Molecular Biology, Lesk, A. N.,
ed., Oxford
University Press, New York (1988), Biocomputing: Informatics and Genome
Projects, Smith,
D. W., ed., Academic Press, New York (1993); Computer Analysis of Sequence
Data, Part I,
Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey (1994);
Sequence
Analysis in Molecular Biology, von Heinge, G., Academic Press (1987); Sequence
Analysis
Primer, Gribskov, M. and Devereux, J., eds., M. Stockton Press, New York
(1991); and
CA 02979840 2017-09-14
WO 2016/149460 PCT/US2016/022787
Carillo, H., and Lipman, D., SIAM J. Applied Math., 48: 1073 (1988); the
teachings of which
are incorporated herein by reference.
[0056] Methods to determine sequence identity are codified in publicly
available computer
programs which determine sequence identity between given sequences. Examples
of such
programs include, but are not limited to, the GCG program package (Devereux,
J., et al.,
Nucleic Acids Research, 12(1):387 (1984)), BLASTP, BLASTN and BLASTX
(Altschul, S.
F. et al., J. Molec. Biol., 215:403-410 (1990). The BLAST programs are
publicly available
from NCBI and other sources (BLAST Manual, Altschul, S. et al., NCVI NLM NIH
Bethesda, Md. 20894, Altschul, S. F. et al., J. Molec. Biol., 215:403-410
(1990), the
teachings of which are incorporated herein by reference). These programs
optimally align
sequences using default gap weights in order to produce the highest level of
sequence identity
between the given and reference sequences.
[0057] In specific embodiments, the immunogenic composition of the instant
disclosure
includes at least one isolated polypeptide, such as at least two, such as at
least three, such as
at least four, such as at least five, such as at least six, such as at least
seven, such as at least
ten, such as at least fifteen, such as at least twenty, such as at least
twenty-five, such as at
least twenty-six isolated polypeptides comprising an amino acid sequence
having a sequence
identity of at least 75%, such as at least 80%, such as at least 85%, such as
at least 90%, such
as at least 95%, such as at least 97%, such as at least 98%, such as at least
99%, such as at
least 100% to a polypeptide selected from SEQ ID NOS: 1-27.
[0058] In other specific embodiments, the immunogenic composition of the
instant disclosure
includes no more than one isolated polypeptide, such as no more than two, such
as no more
than three, such as no more than four, such as no more than five, such as no
more than six,
such as no more than seven, such as no more than ten, such as no more than
fifteen, such as
no more than twenty, such as no more than twenty-five, such as no more than
twenty-six
isolated polypeptides comprising an amino acid sequence having a sequence
identity of at
least 75%, such as at least 80%, such as at least 85%, such as at least 90%,
such as at least
95%, such as at least 97%, such as at least 98%, such as at least 99%, such as
at least 100% to
an amino acid sequence selected from SEQ ID NOS: 1-27.
[0059] In further specific embodiments, the immunogenic composition of the
instant
disclosure includes at least one isolated polypeptide comprising an amino acid
sequence
having a sequence identity of at least 75%, such as at least 80%, such as at
least 85%, such as
at least 90%, such as at least 95%, such as at least 97%, such as at least
98%, such as at least
99%, such as at least 100% to SEQ ID NO: 1 and optionally at least one
additional isolated
11
CA 02979840 2017-09-14
WO 2016/149460 PCT/US2016/022787
polypeptide, such as at least two, such as at least three, such as at least
four, such as at least
five, such as at least six, such as at least seven, such as at least ten, such
as at least fifteen,
such as at least twenty, such as at least twenty-five, such as at least twenty-
six additional
isolated polypeptides comprising an amino acid sequence having a sequence
identity of at
least 75%, such as at least 80%, such as at least 85%, such as at least 90%,
such as at least
95%, such as at least 97%, such as at least 98%, such as at least 99%, such as
at least 100% to
an amino acid sequence selected from SEQ ID NOS: 2-27 or immunogenic fragments
thereof.
[0060] In some embodiments, the immunogenic composition of the instant
disclosure
includes at least one isolated polypeptide comprising an amino acid sequence
having a
sequence identity of at least 75%, such as at least 80%, such as at least 85%,
such as at least
90%, such as at least 95%, such as at least 97%, such as at least 98%, such as
at least 99%,
such as at least 100% to SEQ ID NO: 2 and optionally at least one additional
isolated
polypeptide, such as at least two, such as at least three, such as at least
four, such as at least
five, such as at least six, such as at least seven, such as at least ten, such
as at least fifteen,
such as at least twenty, such as at least twenty-five, such as at least twenty-
six additional
isolated polypeptides comprising an amino acid sequence having a sequence
identity of at
least 75%, such as at least 80%, such as at least 85%, such as at least 90%,
such as at least
95%, such as at least 97%, such as at least 98%, such as at least 99%, such as
at least 100% to
an amino acid sequence selected from SEQ ID NOS: 1, 3 and 4-27.
[0061] In some embodiments, the immunogenic composition of the instant
disclosure
includes at least one isolated polypeptide comprising an amino acid sequence
having a
sequence identity of at least 75%, such as at least 80%, such as at least 85%,
such as at least
90%, such as at least 95%, such as at least 97%, such as at least 98%, such as
at least 99%,
such as at least 100% to SEQ ID NO: 3 and optionally at least one additional
isolated
polypeptide, such as at least two, such as at least three, such as at least
four, such as at least
five, such as at least six, such as at least seven, such as at least ten, such
as at least fifteen,
such as at least twenty, such as at least twenty-five, such as at least twenty-
six additional
isolated polypeptides comprising an amino acid sequence having a sequence
identity of at
least 75%, such as at least 80%, such as at least 85%, such as at least 90%,
such as at least
95%, such as at least 97%, such as at least 98%, such as at least 99%, such as
at least 100% to
an amino acid sequence selected from SEQ ID NOS: 1, 2 and 4-27.
[0062] In some embodiments, the immunogenic composition of the instant
disclosure
includes at least one isolated polypeptide comprising an amino acid sequence
having a
12
CA 02979840 2017-09-14
WO 2016/149460 PCT/US2016/022787
sequence identity of at least 75%, such as at least 80%, such as at least 85%,
such as at least
90%, such as at least 95%, such as at least 97%, such as at least 98%, such as
at least 99%,
such as at least 100% to SEQ ID NO: 4 and optionally at least one additional
isolated
polypeptide, such as at least two, such as at least three, such as at least
four, such as at least
five, such as at least six, such as at least seven, such as at least ten, such
as at least fifteen,
such as at least twenty, such as at least twenty-five, such as at least twenty-
six additional
isolated polypeptides comprising an amino acid sequence having a sequence
identity of at
least 75%, such as at least 80%, such as at least 85%, such as at least 90%,
such as at least
95%, such as at least 97%, such as at least 98%, such as at least 99%, such as
at least 100% to
an amino acid sequence selected from SEQ ID NOS: 1-3 and 5-27.
[0063] In some embodiments, the immunogenic composition of the instant
disclosure
includes at least one isolated polypeptide comprising an amino acid sequence
having a
sequence identity of at least 75%, such as at least 80%, such as at least 85%,
such as at least
90%, such as at least 95%, such as at least 97%, such as at least 98%, such as
at least 99%,
such as at least 100% to SEQ ID NO: 5 and optionally at least one additional
isolated
polypeptide, such as at least two, such as at least three, such as at least
four, such as at least
five, such as at least six, such as at least seven, such as at least ten, such
as at least fifteen,
such as at least twenty, such as at least twenty-five, such as at least twenty-
six additional
isolated polypeptides comprising an amino acid sequence having a sequence
identity of at
least 75%, such as at least 80%, such as at least 85%, such as at least 90%,
such as at least
95%, such as at least 97%, such as at least 98%, such as at least 99%, such as
at least 100% to
an amino acid sequence selected from SEQ ID NOS: 1-4 and 6-27.
[0064] In some embodiments, the immunogenic composition of the instant
disclosure
includes at least one isolated polypeptide comprising an amino acid sequence
having a
sequence identity of at least 75%, such as at least 80%, such as at least 85%,
such as at least
90%, such as at least 95%, such as at least 97%, such as at least 98%, such as
at least 99%,
such as at least 100% to SEQ ID NO: 6 and optionally at least one additional
isolated
polypeptide, such as at least two, such as at least three, such as at least
four, such as at least
five, such as at least six, such as at least seven, such as at least ten, such
as at least fifteen,
such as at least twenty, such as at least twenty-five, such as at least twenty-
six additional
isolated polypeptides comprising an amino acid sequence having a sequence
identity of at
least 75%, such as at least 80%, such as at least 85%, such as at least 90%,
such as at least
95%, such as at least 97%, such as at least 98%, such as at least 99%, such as
at least 100% to
an amino acid sequence selected from SEQ ID NOS: 1-5 and 7-27.
13
CA 02979840 2017-09-14
WO 2016/149460 PCT/US2016/022787
[0065] In some embodiments, the immunogenic composition of the instant
disclosure
includes at least one isolated polypeptide comprising an amino acid sequence
having a
sequence identity of at least 75%, such as at least 80%, such as at least 85%,
such as at least
90%, such as at least 95%, such as at least 97%, such as at least 98%, such as
at least 99%,
such as at least 100% to SEQ ID NO: 7 and optionally at least one additional
isolated
polypeptide, such as at least two, such as at least three, such as at least
four, such as at least
five, such as at least six, such as at least seven, such as at least ten, such
as at least fifteen,
such as at least twenty, such as at least twenty-five, such as at least twenty-
six additional
isolated polypeptides comprising an amino acid sequence having a sequence
identity of at
least 75%, such as at least 80%, such as at least 85%, such as at least 90%,
such as at least
95%, such as at least 97%, such as at least 98%, such as at least 99%, such as
at least 100% to
an amino acid sequence selected from SEQ ID NOS: 1-6 and 8-27.
[0066] In some embodiments, the immunogenic composition of the instant
disclosure
includes at least one isolated polypeptide comprising an amino acid sequence
having a
sequence identity of at least 75%, such as at least 80%, such as at least 85%,
such as at least
90%, such as at least 95%, such as at least 97%, such as at least 98%, such as
at least 99%,
such as at least 100% to SEQ ID NO: 8 and optionally at least one additional
isolated
polypeptide, such as at least two, such as at least three, such as at least
four, such as at least
five, such as at least six, such as at least seven, such as at least ten, such
as at least fifteen,
such as at least twenty, such as at least twenty-five, such as at least twenty-
six additional
isolated polypeptides comprising an amino acid sequence having a sequence
identity of at
least 75%, such as at least 80%, such as at least 85%, such as at least 90%,
such as at least
95%, such as at least 97%, such as at least 98%, such as at least 99%, such as
at least 100% to
an amino acid sequence selected from SEQ ID NOS: 1-7 and 9-27.
[0067] In some embodiments, the immunogenic composition of the instant
disclosure
includes at least one isolated polypeptide comprising an amino acid sequence
having a
sequence identity of at least 75%, such as at least 80%, such as at least 85%,
such as at least
90%, such as at least 95%, such as at least 97%, such as at least 98%, such as
at least 99%,
such as at least 100% to SEQ ID NO: 9 and optionally at least one additional
isolated
polypeptide, such as at least two, such as at least three, such as at least
four, such as at least
five, such as at least six, such as at least seven, such as at least ten, such
as at least fifteen,
such as at least twenty, such as at least twenty-five, such as at least twenty-
six additional
isolated polypeptides comprising an amino acid sequence having a sequence
identity of at
least 75%, such as at least 80%, such as at least 85%, such as at least 90%,
such as at least
14
CA 02979840 2017-09-14
WO 2016/149460 PCT/US2016/022787
95%, such as at least 97%, such as at least 98%, such as at least 99%, such as
at least 100% to
an amino acid sequence selected from SEQ ID NOS: 1-8 and 10-27.
[0068] In some embodiments, the immunogenic composition of the instant
disclosure
includes at least one isolated polypeptide comprising an amino acid sequence
having a
sequence identity of at least 75%, such as at least 80%, such as at least 85%,
such as at least
90%, such as at least 95%, such as at least 97%, such as at least 98%, such as
at least 99%,
such as at least 100% to SEQ ID NO: 10 and optionally least one additional
isolated
polypeptide, such as at least two, such as at least three, such as at least
four, such as at least
five, such as at least six, such as at least seven, such as at least ten, such
as at least fifteen,
such as at least twenty, such as at least twenty-five, such as at least twenty-
six additional
isolated polypeptides comprising an amino acid sequence having a sequence
identity of at
least 75%, such as at least 80%, such as at least 85%, such as at least 90%,
such as at least
95%, such as at least 97%, such as at least 98%, such as at least 99%, such as
at least 100% to
an amino acid sequence selected from SEQ ID NOS: 1-9 and 11-27.
[0069] In some embodiments, the immunogenic composition of the instant
disclosure
includes at least one isolated polypeptide comprising an amino acid sequence
having a
sequence identity of at least 75%, such as at least 80%, such as at least 85%,
such as at least
90%, such as at least 95%, such as at least 97%, such as at least 98%, such as
at least 99%,
such as at least 100% to SEQ ID NO: 11 and optionally at least one additional
isolated
polypeptide, such as at least two, such as at least three, such as at least
four, such as at least
five, such as at least six, such as at least seven, such as at least ten, such
as at least fifteen,
such as at least twenty, such as at least twenty-five, such as at least twenty-
six additional
isolated polypeptides comprising an amino acid sequence having a sequence
identity of at
least 75%, such as at least 80%, such as at least 85%, such as at least 90%,
such as at least
95%, such as at least 97%, such as at least 98%, such as at least 99%, such as
at least 100% to
an amino acid sequence selected from SEQ ID NOS: 1-10 and 12-27.
[0070] In some embodiments, the immunogenic composition of the instant
disclosure
includes at least one isolated polypeptide comprising an amino acid sequence
having a
sequence identity of at least 75%, such as at least 80%, such as at least 85%,
such as at least
90%, such as at least 95%, such as at least 97%, such as at least 98%, such as
at least 99%,
such as at least 100% to SEQ ID NO: 12 and optionally at least one additional
isolated
polypeptide, such as at least two, such as at least three, such as at least
four, such as at least
five, such as at least six, such as at least seven, such as at least ten, such
as at least fifteen,
such as at least twenty, such as at least twenty-five, such as at least twenty-
six additional
CA 02979840 2017-09-14
WO 2016/149460 PCT/US2016/022787
isolated polypeptides comprising an amino acid sequence having a sequence
identity of at
least 75%, such as at least 80%, such as at least 85%, such as at least 90%,
such as at least
95%, such as at least 97%, such as at least 98%, such as at least 99%, such as
at least 100% to
an amino acid sequence selected from SEQ ID NOS: 1-11 and 13-27.
[0071] In some embodiments, the immunogenic composition of the instant
disclosure
includes at least one isolated polypeptide comprising an amino acid sequence
having a
sequence identity of at least 75%, such as at least 80%, such as at least 85%,
such as at least
90%, such as at least 95%, such as at least 97%, such as at least 98%, such as
at least 99%,
such as at least 100% to SEQ ID NO: 13 and optionally at least one additional
isolated
polypeptide, such as at least two, such as at least three, such as at least
four, such as at least
five, such as at least six, such as at least seven, such as at least ten, such
as at least fifteen,
such as at least twenty, such as at least twenty-five, such as at least twenty-
six additional
isolated polypeptides comprising an amino acid sequence having a sequence
identity of at
least 75%, such as at least 80%, such as at least 85%, such as at least 90%,
such as at least
95%, such as at least 97%, such as at least 98%, such as at least 99%, such as
at least 100% to
an amino acid sequence selected from SEQ ID NOS: 1-12 and 14-27.
[0072] In some embodiments, the immunogenic composition of the instant
disclosure
includes at least one isolated polypeptide comprising an amino acid sequence
having a
sequence identity of at least 75%, such as at least 80%, such as at least 85%,
such as at least
90%, such as at least 95%, such as at least 97%, such as at least 98%, such as
at least 99%,
such as at least 100% to SEQ ID NO: 14 and optionally at least one additional
isolated
polypeptide, such as at least two, such as at least three, such as at least
four, such as at least
five, such as at least six, such as at least seven, such as at least ten, such
as at least fifteen,
such as at least twenty, such as at least twenty-five, such as at least twenty-
six additional
isolated polypeptides comprising an amino acid sequence having a sequence
identity of at
least 75%, such as at least 80%, such as at least 85%, such as at least 90%,
such as at least
95%, such as at least 97%, such as at least 98%, such as at least 99%, such as
at least 100% to
an amino acid sequence selected from SEQ ID NOS: 1-13 and 15-27.
[0073] In some embodiments, the immunogenic composition of the instant
disclosure
includes at least one isolated polypeptide comprising an amino acid sequence
having a
sequence identity of at least 75%, such as at least 80%, such as at least 85%,
such as at least
90%, such as at least 95%, such as at least 97%, such as at least 98%, such as
at least 99%,
such as at least 100% to SEQ ID NO: 15 and optionally at least one additional
isolated
polypeptide, such as at least two, such as at least three, such as at least
four, such as at least
16
CA 02979840 2017-09-14
WO 2016/149460 PCT/US2016/022787
five, such as at least six, such as at least seven, such as at least ten, such
as at least fifteen,
such as at least twenty, such as at least twenty-five, such as at least twenty-
six additional
isolated polypeptides comprising an amino acid sequence having a sequence
identity of at
least 75%, such as at least 80%, such as at least 85%, such as at least 90%,
such as at least
95%, such as at least 97%, such as at least 98%, such as at least 99%, such as
at least 100% to
an amino acid sequence selected from SEQ ID NOS: 1-14 and 16-27.
[0074] In some embodiments, the immunogenic composition of the instant
disclosure
includes at least one isolated polypeptide comprising an amino acid sequence
having a
sequence identity of at least 75%, such as at least 80%, such as at least 85%,
such as at least
90%, such as at least 95%, such as at least 97%, such as at least 98%, such as
at least 99%,
such as at least 100% to SEQ ID NO: 16 and optionally at least one additional
isolated
polypeptide, such as at least two, such as at least three, such as at least
four, such as at least
five, such as at least six, such as at least seven, such as at least ten, such
as at least fifteen,
such as at least twenty, such as at least twenty-five, such as at least twenty-
six additional
isolated polypeptides comprising an amino acid sequence having a sequence
identity of at
least 75%, such as at least 80%, such as at least 85%, such as at least 90%,
such as at least
95%, such as at least 97%, such as at least 98%, such as at least 99%, such as
at least 100% to
an amino acid sequence selected from SEQ ID NOS: 1-15 and 17-27.
[0075] In some embodiments, the immunogenic composition of the instant
disclosure
includes at least one isolated polypeptide comprising an amino acid sequence
having a
sequence identity of at least 75%, such as at least 80%, such as at least 85%,
such as at least
90%, such as at least 95%, such as at least 97%, such as at least 98%, such as
at least 99%,
such as at least 100% to SEQ ID NO: 17 and optionally at least one additional
isolated
polypeptide, such as at least two, such as at least three, such as at least
four, such as at least
five, such as at least six, such as at least seven, such as at least ten, such
as at least fifteen,
such as at least twenty, such as at least twenty-five, such as at least twenty-
six additional
isolated polypeptides comprising an amino acid sequence having a sequence
identity of at
least 75%, such as at least 80%, such as at least 85%, such as at least 90%,
such as at least
95%, such as at least 97%, such as at least 98%, such as at least 99%, such as
at least 100% to
an amino acid sequence selected from SEQ ID NOS: 1-16 and 18-27.
[0076] In some embodiments, the immunogenic composition of the instant
disclosure
includes at least one isolated polypeptide comprising an amino acid sequence
having a
sequence identity of at least 75%, such as at least 80%, such as at least 85%,
such as at least
90%, such as at least 95%, such as at least 97%, such as at least 98%, such as
at least 99%,
17
CA 02979840 2017-09-14
WO 2016/149460 PCT/US2016/022787
such as at least 100% to SEQ ID NO: 18 and optionally at least one additional
isolated
polypeptide, such as at least two, such as at least three, such as at least
four, such as at least
five, such as at least six, such as at least seven, such as at least ten, such
as at least fifteen,
such as at least twenty, such as at least twenty-five, such as at least twenty-
six additional
isolated polypeptides comprising an amino acid sequence having a sequence
identity of at
least 75%, such as at least 80%, such as at least 85%, such as at least 90%,
such as at least
95%, such as at least 97%, such as at least 98%, such as at least 99%, such as
at least 100% to
an amino acid sequence selected from SEQ ID NOS: 1-17 and 19-27.
[0077] In some embodiments, the immunogenic composition of the instant
disclosure
includes at least one isolated polypeptide comprising an amino acid sequence
having a
sequence identity of at least 75%, such as at least 80%, such as at least 85%,
such as at least
90%, such as at least 95%, such as at least 97%, such as at least 98%, such as
at least 99%,
such as at least 100% to SEQ ID NO: 19 and optionally at least one additional
isolated
polypeptide, such as at least two, such as at least three, such as at least
four, such as at least
five, such as at least six, such as at least seven, such as at least ten, such
as at least fifteen,
such as at least twenty, such as at least twenty-five, such as at least twenty-
six additional
isolated polypeptides comprising an amino acid sequence having a sequence
identity of at
least 75%, such as at least 80%, such as at least 85%, such as at least 90%,
such as at least
95%, such as at least 97%, such as at least 98%, such as at least 99%, such as
at least 100% to
an amino acid sequence selected from SEQ ID NOS: 1-18 and 20-27.
[0078] In some embodiments, the vaccine composition of the instant disclosure
includes at
least one isolated polypeptide comprising an amino acid sequence having a
sequence identity
of at least 75%, such as at least 80%, such as at least 85%, such as at least
90%, such as at
least 95%, such as at least 97%, such as at least 98%, such as at least 99%,
such as at least
100% to SEQ ID NO: 20 and optionally at least one additional isolated
polypeptide, such as
at least two, such as at least three, such as at least four, such as at least
five, such as at least
six, such as at least seven, such as at least ten, such as at least fifteen,
such as at least twenty,
such as at least twenty-five, such as at least twenty-six additional isolated
polypeptides
comprising an amino acid sequence having a sequence identity of at least 75%,
such as at
least 80%, such as at least 85%, such as at least 90%, such as at least 95%,
such as at least
97%, such as at least 98%, such as at least 99%, such as at least 100% to an
amino acid
sequence selected from SEQ ID NOS: 1-19 and 21-27.
[0079] In some embodiments, the immunogenic composition of the instant
disclosure
includes at least one isolated polypeptide comprising an amino acid sequence
having a
18
CA 02979840 2017-09-14
WO 2016/149460 PCT/US2016/022787
sequence identity of at least 75%, such as at least 80%, such as at least 85%,
such as at least
90%, such as at least 95%, such as at least 97%, such as at least 98%, such as
at least 99%,
such as at least 100% to SEQ ID NO: 21 and optionally at least one additional
isolated
polypeptide, such as at least two, such as at least three, such as at least
four, such as at least
five, such as at least six, such as at least seven, such as at least ten, such
as at least fifteen,
such as at least twenty, such as at least twenty-five, such as at least twenty-
six additional
isolated polypeptides comprising an amino acid sequence having a sequence
identity of at
least 75%, such as at least 80%, such as at least 85%, such as at least 90%,
such as at least
95%, such as at least 97%, such as at least 98%, such as at least 99%, such as
at least 100% to
an amino acid sequence selected from SEQ ID NOS: 1-20 and 22-27.
[0080] In some embodiments, the immunogenic composition of the instant
disclosure
includes at least one isolated polypeptide comprising an amino acid sequence
having a
sequence identity of at least 75%, such as at least 80%, such as at least 85%,
such as at least
90%, such as at least 95%, such as at least 97%, such as at least 98%, such as
at least 99%,
such as at least 100% to SEQ ID NO: 22 and optionally at least one additional
isolated
polypeptide, such as at least two, such as at least three, such as at least
four, such as at least
five, such as at least six, such as at least seven, such as at least ten, such
as at least fifteen,
such as at least twenty, such as at least twenty-five, such as at least twenty-
six additional
isolated polypeptides comprising an amino acid sequence having a sequence
identity of at
least 75%, such as at least 80%, such as at least 85%, such as at least 90%,
such as at least
95%, such as at least 97%, such as at least 98%, such as at least 99%, such as
at least 100% to
an amino acid sequence selected from SEQ ID NOS: 1-21 and 23-27.
[0081] In some embodiments, the immunogenic composition of the instant
disclosure
includes at least one isolated polypeptide comprising an amino acid sequence
having a
sequence identity of at least 75%, such as at least 80%, such as at least 85%,
such as at least
90%, such as at least 95%, such as at least 97%, such as at least 98%, such as
at least 99%,
such as at least 100% to SEQ ID NO: 23 and optionally at least one additional
isolated
polypeptide, such as at least two, such as at least three, such as at least
four, such as at least
five, such as at least six, such as at least seven, such as at least ten, such
as at least fifteen,
such as at least twenty, such as at least twenty-five, such as at least twenty-
six additional
isolated polypeptides comprising an amino acid sequence having a sequence
identity of at
least 75%, such as at least 80%, such as at least 85%, such as at least 90%,
such as at least
95%, such as at least 97%, such as at least 98%, such as at least 99%, such as
at least 100% to
an amino acid sequence selected from SEQ ID NOS: 1-22 and 24-27.
19
CA 02979840 2017-09-14
WO 2016/149460 PCT/US2016/022787
[0082] In some embodiments, the immunogenic composition of the instant
disclosure
includes at least one isolated polypeptide comprising an amino acid sequence
having a
sequence identity of at least 75%, such as at least 80%, such as at least 85%,
such as at least
90%, such as at least 95%, such as at least 97%, such as at least 98%, such as
at least 99%,
such as at least 100% to SEQ ID NO: 24 and optionally at least one additional
isolated
polypeptide, such as at least two, such as at least three, such as at least
four, such as at least
five, such as at least six, such as at least seven, such as at least ten, such
as at least fifteen,
such as at least twenty, such as at least twenty-five, such as at least twenty-
six additional
isolated polypeptides comprising an amino acid sequence having a sequence
identity of at
least 75%, such as at least 80%, such as at least 85%, such as at least 90%,
such as at least
95%, such as at least 97%, such as at least 98%, such as at least 99%, such as
at least 100% to
an amino acid sequence selected from SEQ ID NOS: 1-23 and 25-27.
[0083] In some embodiments, the immunogenic composition of the instant
disclosure
includes at least one isolated polypeptide comprising an amino acid sequence
having a
sequence identity of at least 75%, such as at least 80%, such as at least 85%,
such as at least
90%, such as at least 95%, such as at least 97%, such as at least 98%, such as
at least 99%,
such as at least 100% to SEQ ID NO: 25 and optionally at least one additional
isolated
polypeptide, such as at least two, such as at least three, such as at least
four, such as at least
five, such as at least six, such as at least seven, such as at least ten, such
as at least fifteen,
such as at least twenty, such as at least twenty-five, such as at least twenty-
six additional
isolated polypeptides comprising an amino acid sequence having a sequence
identity of at
least 75%, such as at least 80%, such as at least 85%, such as at least 90%,
such as at least
95%, such as at least 97%, such as at least 98%, such as at least 99%, such as
at least 100% to
an amino acid sequence selected from SEQ ID NOS: 1-24 and 26-27.
[0084] In some embodiments, the immunogenic composition of the instant
disclosure
includes at least one isolated polypeptide comprising an amino acid sequence
having a
sequence identity of at least 75%, such as at least 80%, such as at least 85%,
such as at least
90%, such as at least 95%, such as at least 97%, such as at least 98%, such as
at least 99%,
such as at least 100% to SEQ ID NO: 26 and optionally at least one additional
isolated
polypeptide, such as at least two, such as at least three, such as at least
four, such as at least
five, such as at least six, such as at least seven, such as at least ten, such
as at least fifteen,
such as at least twenty, such as at least twenty-five, such as at least twenty-
six additional
isolated polypeptides comprising an amino acid sequence having a sequence
identity of at
least 75%, such as at least 80%, such as at least 85%, such as at least 90%,
such as at least
CA 02979840 2017-09-14
WO 2016/149460 PCT/US2016/022787
95%, such as at least 97%, such as at least 98%, such as at least 99%, such as
at least 100% to
an amino acid sequence selected from SEQ ID NOS: 1-25 and SEQ ID NO: 27.
[0085] In some embodiments, the immunogenic composition of the instant
disclosure
includes at least one isolated polypeptide comprising an amino acid sequence
having a
sequence identity of at least 75%, such as at least 80%, such as at least 85%,
such as at least
90%, such as at least 95%, such as at least 97%, such as at least 98%, such as
at least 99%,
such as at least 100% to SEQ ID NO: 27 and optionally at least one additional
isolated
polypeptide, such as at least two, such as at least three, such as at least
four, such as at least
five, such as at least six, such as at least seven, such as at least ten, such
as at least fifteen,
such as at least twenty, such as at least twenty-five, such as at least twenty-
six additional
isolated polypeptides comprising an amino acid sequence having a sequence
identity of at
least 75%, such as at least 80%, such as at least 85%, such as at least 90%,
such as at least
95%, such as at least 97%, such as at least 98%, such as at least 99%, such as
at least 100% to
an amino acid sequence selected from SEQ ID NOS: 1-26.
[0086] In some embodiments, the polypeptides of the present disclosure are
recombinant
polypeptides. The term "recombinant polypeptide" refers to a protein produced
by
recombinant expression methods, such as, for example, in prokaryotic or
eukaryotic host
cells, or in cell-free in vitro expression systems.
[0087] The polypeptides of the present disclosure are typically expressed
using an expression
vector and purified. Expression vectors may be either self-replicating
extrachromosomal
vectors or vectors that integrate into a host genome. Generally, expression
vectors include
transcriptional and translational regulatory nucleic acid sequences, operably
linked to the
nucleic acid encoding the target protein.
[0088] In some embodiments, control sequences may be used for the expression
of an
operably linked coding sequence in a particular host organism. The control
sequences that
are suitable for prokaryotes, for example, include a promoter, optionally an
operator
sequence, and a ribosome binding site. Eukaryotic cells are known to use
promoters,
polyadenylation signals, and enhancers. A nucleic acid sequence is "operably
linked" when
it is placed into a functional relationship with another nucleic acid
sequence. For example,
DNA for a pre-sequence or secretory leader is operably linked to DNA if it is
expressed as a
pre-protein that participates in the secretion of the polypeptide; a promoter
or enhancer is
operably linked to a coding sequence if it affects the transcription of the
sequence; or a
ribosome binding site is operably linked to a coding sequence if it is
positioned so as to
facilitate translation. Operably linked DNA sequences may be contiguous or non-
contiguous.
21
CA 02979840 2017-09-14
WO 2016/149460 PCT/US2016/022787
Methods for linking DNA sequences are well-known in the art and include use of
the
polymerase chain reaction and ligation. The transcriptional and translational
regulatory
nucleic acid will generally be appropriate to the host cell used to express
the target protein;
for example, transcriptional and translational regulatory nucleic acid
sequences from E. coil
are typically used to express the target protein in E. coil.
[0089] Numerous types of appropriate expression vectors, and suitable
regulatory sequences
are known in the art for a variety of host cells. Methods for expressing
polypeptides are well
known in the art (e.g., Sambrook et al. (1989) Molecular Cloning, A Laboratory
Manual, 2nd
ed., vol. 1-3, Cold Spring Harbor Laboratory; Berger and Kimmel (1987) Guide
to Molecular
Cloning Techniques, Methods in Enzymology, vol. 152, Academic Press, Inc., San
Diego,
Calif.; Ausubel et al. (1995) Current Protocols in Molecular Biology, John
Wiley & Sons,
Inc., NY) herein incorporated by reference in their entireties.
[0090] The polypeptides of the present disclosure may be produced by culturing
a host cell
transformed with an expression vector containing nucleic acid encoding
polypeptides of the
present disclosure, such as encoding one or more of SEQ ID NOS: 1-27 or
immunogenic
fragments or variants thereof, under the appropriate conditions to induce or
cause expression
of the polypeptides of the present disclosure. The conditions appropriate for
protein
expression will vary with the choice of the expression vector and the host
cell, and may be
easily determined by one skilled in the art using routine experimentation.
[0091] Appropriate host cells include yeast, bacteria, archaebacteria, fungi,
insect cells, and
animal cells, including mammalian cells (such as human cells and cells lines).
Thus, host
cells include, but are not limited to, Drosophila melanogaster cells,
Tetrahymena,
Saccharomyces cerevisiae and other yeasts, E. coil, Bacillus subtilis, SD
cells, C129 cells,
293 cells, Neurospora, BHK, CHO, COS, HeLa cells, Hep G2 cells, THP1 cell line
(a
macrophage cell line), and human embryonic kidney cell lines (e.g., HEK293).
[0092] Nucleic acid molecules encoding the polypeptides of the present
disclosure may be
cloned using standard molecular biological methods, including DNA
amplification methods,
such as the polymerase chain method (PCR) (see e.g., Sambrook et al.
(1989)Molecular
Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbour, N.Y.; Berger &
Kimmel
(1987) Methods in Enzymology. Vol. 152: Guide to Molecular Cloning Techniques,
Academic Press, Inc., San Diego, Calif.; Co et al. (1992) J. Immunol.
148:1149), which are
each herein incorporated by reference. Thus, for example, a nucleic acid
molecule encoding
a polypeptide of the present disclosure may be PCR-amplified using a sense
primer
containing one restriction site and an antisense primer containing another
restriction site.
22
CA 02979840 2017-09-14
WO 2016/149460 PCT/US2016/022787
This will produce a nucleic acid encoding the desired sequence or subsequence
having
terminal restriction sites. This nucleic acid can then readily be ligated into
a vector having
appropriate corresponding restriction sites. Suitable PCR primers may be
chosen by one of
skill in the art based on the sequence to be expressed. Appropriate
restriction sites can also
be added by site-directed mutagenesis as is well known in the art.
[0093] The methods of introducing exogenous nucleic acids into host cells are
also well
known in the art, and will vary with the host cell used. Suitable techniques
include, but are
not limited to, dextran-mediated transfection, calcium phosphate
precipitation, polybrene
mediated transfection, protoplast fusion, electroporation, viral infection,
encapsulation of the
nucleic acids in liposomes, and direct microinjection of nucleic acids into
nuclei.
[0094] The polypeptides of the present disclosure may be isolated or purified
in a variety of
ways known to those skilled in the art depending on what other components are
present in the
sample. Standard purification methods include electrophoretic, molecular,
immunological,
and chromatographic techniques, including ion exchange, hydrophobic, affinity,
and reverse-
phase HPLC chromatography.
[0095] Some embodiments of the disclosure provide synthetic polypeptides of
the present
disclosure. Polypeptides having up to about 100-150 amino acid residues may be
prepared
by in vitro synthesis using established techniques. Synthetic polypeptides may
be prepared
by chemical synthesis (such as solid phase peptide synthesis) using methods
known in the art.
[0096] In some embodiments, the immunogenic composition of the present
disclosure
includes a pharmaceutically acceptable carrier. The carrier must be
"acceptable" in the sense
that it is compatible with the active ingredient of the composition, and
typically, capable of
stabilizing the active ingredient and not deleterious to the subject to be
treated. In some
embodiments, the pharmaceutically acceptable carrier is a non-naturally
occurring
pharmaceutically acceptable carrier.
[0097] The pharmaceutically acceptable carriers (vehicles) may be
conventional, but are not
limited to conventional carriers (vehicle). For example, E. W. Martin,
Remington's
Pharmaceutical Sciences, Mack Publishing Co., Easton, PA, 15th Edition (1975)
and D. B.
Troy, ed. Remington: The Science and Practice of Pharmacy, Lippincott Williams
& Wilkins,
Baltimore MD and Philadelphia, PA, 21st Edition (2006) describe compositions
and
formulations suitable for pharmaceutical delivery of one or more molecules and
additional
pharmaceutical agents.
[0098] The present immunogenic compositions may comprise buffers (e.g., sodium
phosphate, histidine, potassium phosphate, sodium citrate, potassium citrate,
maleic acid,
23
CA 02979840 2017-09-14
WO 2016/149460 PCT/US2016/022787
ammonium acetate, tris-(hydroxymethyl)-aminomethane (tris), acetate,
diethanolamine, etc.),
amino acids (e.g., argenine, cysteine, histidine, glycine, serine, lysine,
alanine, glutamic acid,
proline), sodium chloride, potassium chloride, sodium citrate, sucrose,
glucose, mannitol,
lactose, glycerol, xylitol, sorbitol, maltose, inositol, trehalose, bovine
serum albumin (BSA),
albumin (e.g., human serum albumin, recombinant albumin), dextran, PVA,
hydroxypropyl
methylcellulose (HPMC), polyethyleneimine, gelatin, polyvinylpyrrolidone
(PVP),
hydroxyethylcellulose (HEC), polyethylene glycol (PEG), ethylene glycol,
dimethylsulfoxide
(DMSO), dimethylformamide (DMF), hydrochloride, sacrosine, gamma-aminobutyric
acid,
Tween-20, Tween-80, sodium dodecyl sulfate (SDS), polysorbate, polyoxyethylene
copolymer, sodium acetate, ammonium sulfate, magnesium sulfate, sodium
sulfate,
trimethylamine N-oxide, betaine, zinc ions, copper ions, calcium ions,
manganese ions,
magnesium ions, CHAPS, sucrose monolaurate, 2-0-beta-mannoglycerate, the like,
or a
combination thereof.
[0099] In some embodiments, the present immunogenic compositions may comprise
propellants (e.g., hydrofluoroalkane (HFA)) for aerosol delivery. In some
embodiments, the
immunogenic compositions of the present disclosure may be formulated as
described in U.S.
Patent No. 5,192,743 that form a gel when reconstituted and which can improve
stability of a
protein of interest (e.g., for storage).
[00100] Immunogenic compositions of the present disclosure may be
appropriately
constructed for some or all routes of administration, for example topical
administration
(including inhalation and nasal administration), oral or enteral
administration, intravenous or
parenteral administration, transdermal administration, epidural administration
or the like. For
example, parenteral formulations usually comprise injectable fluids that
include
pharmaceutically and physiologically acceptable fluids such as water,
physiological saline,
balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle.
For solid
compositions (for example, powder, pill, tablet, or capsule forms),
conventional non- toxic
solid carriers can include, for example, pharmaceutical grades of mannitol,
lactose, starch, or
magnesium stearate. In addition to biologically-neutral carriers, immunogenic
compositions
to be administered can contain minor amounts of non- toxic auxiliary
substances, such as
wetting or emulsifying agents, preservatives, and pH buffering agents and the
like, for
example sodium acetate or sorbitan monolaurate.
[00101] In some embodiments, a parenteral formulation may comprise injectable
fluids that
include pharmaceutically and physiologically acceptable fluids such as water,
physiological
saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a
vehicle.
24
CA 02979840 2017-09-14
WO 2016/149460 PCT/US2016/022787
[00102] For solid compositions (for example, powder, pill, tablet, or capsule
forms),
conventional non-toxic solid carriers can include, for example, pharmaceutical
grades of
mannitol, lactose, starch, or magnesium stearate. In addition to biologically-
neutral carriers,
pharmaceutical compositions to be administered can contain minor amounts of
non- toxic
auxiliary substances, such as wetting or emulsifying agents, preservatives,
and pH buffering
agents and the like, for example sodium acetate or sorbitan monolaurate.
[00103] The aforementioned immunogenic compositions and protein modifications
to
increase protein stability can be applied as described in U.S. Patent
Application 2009/032692,
which is herein incorporated by reference in its entirety.
[00104] In some embodiments the pharmaceutically acceptable carrier of the
present
disclosure includes an adjuvant, such as a non-naturally occurring adjuvant.
As used herein,
an "adjuvant" is understood as a pharmacological or immunological agent that
modifies the
effect of other agents (e.g., immunogen or target antigen in an immunogenic
composition)
while having few if any direct effects when given by itself. In some
embodiments, an
adjuvant will enhance the recipient's immune response to the polypeptides in
the present
immunogenic composition while keeping the injected foreign material at a
minimum.
[00105] Suitable adjuvants are well known in the art (see, for example,
Vaccine Design-The
Subunit and Adjuvant Approach (1995) Pharmaceutical Biotechnology, Volume 6
(eds.
Powell, M. F., & Newman, M. J.) Plenum Press, New York and London, ISBN 0-306-
44867-
X), which is incorporated herein by reference in its entirety. Examples of
adjuvants include,
but are not limited to, alum-precipitate, Freund's complete adjuvant, Freund's
incomplete
adjuvant, monophosphoryl-lipid A/trehalose dicorynomycolate adjuvant, water in
oil
emulsion containing Corynebacterium parvum and tRNA, and other substances that
accomplish the task of increasing immune response by mimicking specific sets
of
evolutionarily conserved molecules including liposomes, lipopolysaccharide (LP
5),
molecular cages for antigen, components of bacterial cell walls, and
endocytosed nucleic
acids such as double-stranded RNA, single-stranded DNA, and unmethylated CpG
dinucleotide-containing DNA. Other examples include cholera toxin, E. coli
heat-labile
enterotoxin, liposome, immune-stimulating complex (ISCOM), immunostimulatory
sequences oligodeoxynucleotide, and aluminum hydroxide.
[00106] Other exemplary adjuvants include the adjuvants described in Lanar et
al., U.S. Pat.
No. 7,029,685 and U.S. Patent Publication No. 2006/0073171, herein
incorporated by
reference in their entireties. Alternatively, the polypeptides of the
immunogenic composition
described herein can be used without any adjuvant.
CA 02979840 2017-09-14
WO 2016/149460 PCT/US2016/022787
Methods
[00107] The present disclosure is further directed to methods for preventing
or treating
filarial diseases. As used herein, "filarial diseases" refer to diseases
caused by thread-like
nematodes (filariae) that belong to the roundworm superfamily filarioidea
family Filariidae.
Such diseases include, but are not limited to lymphatic filariasis, river
blindness, loiasis or
heartworm. As used herein "preventing" refers to the administration of a
therapeutically
effective amount of a polypeptide, immunogenic composition, such as a vaccine,
of the
present disclosure to an animal in order to protect the animal from the
development of, for
example, lymphatic filariasis, river blindness, loiasis, heartworm or the
symptoms thereof In
some embodiments, the immunogenic composition of the disclosure is
administered to a
subject that is at risk for developing a lymphatic filariasis, river
blindness, loiasis or
heartworm.
[00108] By "treating" a disease associated with filarial infection such as
lymphatic filariasis,
river blindness, loiasis or heartworm is intended administration of a
therapeutically effective
amount of a polypeptide, immunogenic composition, such as a vaccine of the
present
disclosure to an animal that has, for example, lymphatic filariasis, river
blindness, loiasis or
heartworm or that has been exposed to a filarial infection, such as a filarial
worm selected
from Brugia malyai, Wuchereria bancrofti, Onchocerca volvulus, Loa loa, or
Dirofilaria
immitis, where the purpose is to cure, heal, alleviate, relieve, alter,
remedy, ameliorate,
improve, or affect the condition or the symptoms of the lymphatic filariasis,
river blindness,
loiasis or heartworm.
[00109] The immunogenic compositions of the present disclosure may be
administered to a
subject. In some embodiments, the subject is a mammal, e.g., a non-human
primate such as
a baboon or macaque. In some embodiments, the subject mammal is a human. The
subject
mammal can also include, but is not limited to, pet or companion animals (e.g.
cats, dogs,
house rabbits, ferrets, rodents, including gerbils, hamsters, chinchillas,
rats, mice, guinea
pigs, etc); working animals, such as guide animals (e.g., monkeys; herding
animals, etc.),
draught animals (e.g., draught horses, oxen, camels, elephants, oxen, camels,
donkeys) and
sport animals (e.g., racing or show-jumping horses); livestock (e.g., alpaca,
banteng, bison,
camel, cattle, deer, donkey, gayal, goat, llama, mule, pig, reindeer, sheep,
water buffalo, yak,
etc. ); laboratory animals (e.g., mice, rabbits, rats, non-human primates);
and undomesticated
animals held in captivity, e.g. in zoological parks and the like. In other
embodiments,
26
CA 02979840 2017-09-14
WO 2016/149460 PCT/US2016/022787
particularly when the disease being prevented or treated is heartworm, the
subject is a dog or
a cat, typically a dog.
[00110] In various embodiments, a therapeutically effective amount of the
immunogenic
composition described herein is administered to the subject. As
used herein "a
therapeutically effective amount" is an amount that provides a therapeutic
effect for a given
condition and administration regimen. In
particular aspects of the disclosure, a
"therapeutically effective amount" refers to an amount of a polypeptide,
immunogenic
composition, or vaccine of the present disclosure that when administered to an
animal brings
about a positive therapeutic response with respect to the prevention or
treatment of a subject
for diseases or conditions associated with filarial worms such as Brugia
malyai, Wuchereria
bancrofti, Onchocerca volvulus, Loa loa, or Dirofilaria immitis. For example,
a positive
therapeutic response in regard to treating diseases or conditions associated
with filarial
worms includes curing or ameliorating the symptoms of the disease.
[00111] A positive therapeutic response with respect to preventing a condition
associated
with a filarial infection includes, for example, the production of filarial
antibodies by the
subject in a quantity sufficient to protect against development of the
disease. The production
of antibodies elicited by a treatment is readily ascertained by obtaining a
plasma or serum
sample from the subject to which an immunogenic composition is administered,
and assaying
the antibodies therein for their ability to bind to the polypeptide(s) used to
elicit the immune
response to filarial worms. Exemplary methods include, but are not limited to,
ELISA
assays, immunofluorescence assays (IFA), or other immunoassays such as a
Western blots, as
is well known in the art.
[00112] The exact dosage is chosen by the individual physician in view of the
patient to be
treated. Dosage and administration are adjusted to provide sufficient levels
of the active
moiety or to maintain the desired effect. Additional factors that may be taken
into account
include the prevalence of filarial worms in the geographical vicinity of the
patient, the
severity of the disease state of the patient, age, and weight of the patient,
diet, time and
frequency of administration, drug combination(s), reaction sensitivities, and
tolerance/response to therapy. An appropriate effective amount may be readily
determined
using only routine experimentation. Several doses may be needed per individual
in order to
achieve a sufficient response to effect treatment. Suitable regimes for
initial administration
and follow-up administration (e.g., booster shots) are also variable, but are
typified by an
initial administration followed in intervals (weeks or months) by a subsequent
administration.
27
CA 02979840 2017-09-14
WO 2016/149460 PCT/US2016/022787
In some embodiments, typical dosages may range from about 0.01 to about 20
mg/kg, and
more particularly from about 0.1 to about 10 mg/kg.
EXAMPLES
Example IL. Materials and Methods
Dissections
[00113] Adult Brugia malayi worms were received in multiple shipments from TRS
Labs
(Athens, GA) and frozen at -80 C until processing. For separation of anatomic
structures,
worms were thawed at room temperature and then dissected using a
stereomicroscope and
fine tipped forceps. One set of forceps was used to grip and steady the center
of the parasite
after thawing and placement into a petri dish filled with phosphate buffered
saline (PBS).
Another set of forceps was used to grasp and gently twist the parasite close
to the first set of
forceps, resulting in a tear of the body wall. The cephalic tip of the body
wall was then
grasped and gently peeled away from the rest of the organs. The caudal portion
of the body
wall was then peeled away from the intestines and uterine tubes (FIG. 2).
Reproductive
organs were identified by their anterior junction and then separated from the
intestine. Each
anatomic fraction (intestine, reproductive tract, and body wall) was placed in
a
microcentrifuge tube filled with PBS. These were stored at -20 C until protein
extraction.
Protein Extraction
[00114] The samples were thawed and then centrifuged in 1.5 ml eppendorf
tubes. The
pelleted tissues were frozen and thawed 4 times by cycling through placement
on dry ice for
minutes followed by placement in a 37 C water bath. Using a mini disposable
micropestle, the samples were homogenized with 50 pi of UPX extraction buffer
(Expedeon).
The micropestle was washed with 50 11.1 of UPX extraction buffer and processed
as per the
manufacturer's instructions. In brief, samples were placed in a 100 C water
bath for 5
minutes, removed and cooled at 4 C for one hour. Samples were then centrifuged
at 15,000 x
g for 10 minutes and supernatant was collected.
[00115] Protein Concentrations were measured by BCA assay. 400 tg proteins of
intestine,
body wall and reproductive tract each were reduced, alkylated and trypsin
digested overnight
following filter-aided digestion procedure using a FASP digestion kit (Protein
Discovery, San
Diego, CA) according to vendor protocol. Tryptic peptides were further
desalted, lyophilized
and reconstituted in 25% acetonitrile with 0.1% formic acid and further
fractionated using
28
CA 02979840 2017-09-14
WO 2016/149460 PCT/US2016/022787
strong cation exchange (SCX) chromatography. The SCX fractions of the three
samples were
pooled into 16 to 18 fractions each, lyophilized and reconstituted in 0.1%
trifluoroacetic acid
to be analyzed by liquid chromatography-mass spectrometry (LC-MS).
Nanobore reversed-phase liquid chromatography tandem MS (nanoRPLC-MSMS)
[00116] Nanobore RPLC-MSMS was performed using an Agilent 1200 nanoflow LC
system
coupled online with a LTQ Orbitrap XL mass spectrometer. The RPLC column (75
p.m i.d. x
cm) were slurry-packed in-house with 5 p.m, 300A pore size C-18 stationary
phase into
fused silica capillaries with a flame pulled tip. After sample injection, the
column was
washed for 20 minutes with 98% mobile phase A (0.1% formic acid in water) at
0.5 1/min.
Peptides were eluted using a linear gradient of 2% mobile phase B (0.1% formic
acid in
acetonitrile) to 35% B in 100 minutes, then to 80% B over an additional 40
minutes. The
column flow-rate was maintained at 0.25 1/min throughout the separation
gradient. The
mass spectrometer was operated in a data-dependent mode in which each full MS
scan was
followed by seven MS/MS scans wherein the seven most abundant molecular ions
were
dynamically selected for collision-induced dissociation (CID) using a
normalized collision
energy of 35%.
Protein identification
[00117] The LC-MS/MS data were searched using SEQUEST through Bioworks
interface
against a combined database of Brugia malayi database downloaded from The
Institute for
Genomic Research (TIGR) and the Wolbachia database from New England Biolabs
(Beverly,
MA). SEQUEST was searched with a fragment ion mass tolerance of 0.50 Da and a
parent
ion tolerance of 25 PPM. Carbamidomethyl of cysteine was specified in SEQUEST
as a
fixed modification. Oxidation of methionine was specified in SEQUEST as a
variable
modification. Scaffold (version Scaffold 3.5.2, Proteome Software Inc.,
Portland, OR) was
used to validate MS/MS based peptide and protein identifications. Peptide
identifications
were accepted if they could be established at greater than 95.0% probability
by the Peptide
Prophet algorithm (Keller et al., 2002, Anal. Chem., 74, 5383-5392, herein
incorporated by
reference). Protein identifications were accepted if they could be established
at greater than
99.0% probability and contained at least 2 identified peptides. Protein
probabilities were
assigned by the Protein Prophet algorithm (Nesvizhskii et al., 2003, Anal.
Chem., 75, 4646-
4658, herein incorporated by reference). Proteins that contained similar
peptides and could
not be differentiated based on MS/MS analysis alone were grouped to satisfy
the principles of
29
CA 02979840 2017-09-14
WO 2016/149460 PCT/US2016/022787
parsimony. TIGR accession numbers were matched to PUB loci from the proteome
published by Bennuru et. Al., 2011, Proc. Natl. Acad.Sci. U. S. A., 108, 9649-
9654, herein
incorporated by reference.
Heat Map Analysis
[00118] A heat map of the relative abundance of each protein, defined as the
number of
unique matching peptides within each anatomic fraction, was made with JMP
software.
Quantitative analysis
[00119] Protein quantitation was determined by normalized spectral abundance.
This
approach provides a theoretical quantitative value useful for determining
relative abundance
of a single protein between samples (McIlwain et al., 2012, BMC
Bioinformatics, 13, 308,
Paoletti et al.., 2006, Proc. Natl. Acad. Sci. U. S. A., 103, 18928-18933) and
an estimation of
relative abundance between different proteins in one sample (Liu et al., 2004,
Anal.
Chem.,76, 4193-4201). Exclusive spectral counts, spectra that match to only 1
protein, were
first divided by the length of the protein to account for the differences in
numbers of possible
spectra. This calculation provides the spectral abundance factor. This was
then normalized
to obtain the normalized spectral abundance factor (NSAF) by dividing by the
sum of the
,Spectra,
total spectral abundance factors found within that anatomic fraction. NSAF =
Length J P V. ,Spectra =
Lip=1 length JP
NSAF enrichment was then calculated by dividing the NSAF of a given protein in
the target
fraction divided by the sum of the NSAF of the other two fractions to
determine whether a
protein was more abundant or "enriched" in one fraction compared to the
others. NSAF
NSAF (target fraction)
Proteins were considered enriched when they
enrichment¨ NSAF of other two fractions (added) =
had an NSAF enrichment value of 2 or greater.
CA 02979840 2017-09-14
WO 2016/149460 PCT/US2016/022787
Functional categories for gene set enrichment analysis (GSEA)
[00120] The proteome of B. malayi had previously been functionally
characterized by
Bennuru and colleagues (Bennuru, et al., 2011). For proteins previously
annotated for
function, no further analysis of function was carried out. The 665 newly
identified proteins
were annotated based loosely on the KOG and PFAM functions. Categories of
function were
used as previously described (Bennuru, et al., 2011), including cytoskeletal,
extracellular
matrix, immunological, metabolism, nuclear regulation, protein export, protein
modification,
protein synthesis, signal transduction, transcription, transporters, and
uncharacterized.
Functions of anatomic fractions were analyzed based on GSEA, which analyzes
the data for
bias in a condition (or anatomic fraction) (Subramanian et al., 2005, Proc.
Natl. Acad. Sci. U.
S. A., 102, 15545-15550, herein incorporated by reference). Proteins were
ranked according
to abundance using spectral counts. A priori defined sets of proteins, based
on functional
annotation, were then analyzed using GSEA for bias within each anatomic
fraction.
BLASTp
[00121] BLASTp was performed on proteins of interest from B. malayi to
identify similarity
among W. bancrofti, 0. volvulus, D. immitis, L. loa, and H. sapiens. BLAST
query was
conducted with blast+ 2.2.29 downloaded from NCBI. Protein databases for W.
bancrofti, 0.
volvulus, H. sapiens, L. boa were downloaded from uniprotKB. Protein database
for D.
immitis was downloaded from nematodes.org. A FASTA file containing the B.
malayi
proteins of interest were blasted against each other genome individually.
Percent identity and
query coverage were recorded for the top scoring sequence for each protein.
Score is
determined by an algorithm that takes into account similarity of AA sequence,
gaps in
homologous regions, and length of homology. Percent identity is defined as the
percentage
of amino acids that match perfectly over the sequence region with greatest
homology.
Example 2. Results
Distinct anatomic fractions exhibit markedly different expression of proteins
[00122] Based on a match of 2 unique peptides to a protein, we identified a
total of 5023
proteins. Of these, 204 were Wolbachia proteins, and 34 could be matched to
more than 1
specific protein, leaving 4,785 specifically identified B. malayi proteins.
While 1,895 of the
proteins were identified by two peptides in all three anatomical fractions of
the parasite, 396
31
CA 02979840 2017-09-14
WO 2016/149460 PCT/US2016/022787
proteins were identified solely within the intestine, 114 solely within the
body wall, and 1011
solely within the uterine tubes (data not shown). Additionally, although the
majority of
proteins were present in all three anatomic fractions, we found that there was
a differential
expression of each protein among the anatomic fractions (FIG. 3).
Proteomic profiling of the B. malayi intestine is consistent with functional
absorption
and digestion
[00123] Like all nematodes, filarial parasites have a fully formed intestine.
However, the
functionality of this tract is not completely clear (Munn, E. A. and Munn, P.
D., 2002,
Feeding and Digestion. In: Lee, D. L., (Ed., The Biology of Nematodes. CRC
Press Taylor
and Francis Group, Boca Raton, Fl, pp. 211-233, herein incorporated by
reference). We
performed several analyses to further elucidate the possible function of the
intestine in B.
malayi. First, gene set enrichment analysis (GSEA) was performed which showed
a bias for
proteins with transporter function to be present within the intestine (FIG.
4). Next, we rank
ordered the proteins that were enriched within the intestine based on their
NSAF value, a
measure which takes into account the number of spectra uniquely matching to a
protein and
the length of the protein in amino acids. Spectral counting has previously
been shown to be
useful to determine relative abundance of a single protein in different
samples (McIlwain, et
al., 2012, Paoletti, et al., 2006) and provide a reasonable approximation of
protein abundance
within a sample compared to other proteins in the same sample (Liu, et al.,
2004). Of the 20
most abundant, enriched, and named intestine proteins, 3 are proteolytic
enzymes
(Bml 00205, Bml 18805, Bml 34740), 2 are transporters (Bml 42930, and Bml
24840),
and 1 is associated with phagocytosis (Bml 02265). The abundance of such
proteins
suggests the intestine is involved in both digestion and active absorption of
nutrients. Of the
remaining 20 most abundant named proteins in the intestine, 3 are muscle
associated proteins
(Bml 28910, Bml 45035, Bml 00655) and the rest are involved in various
functions
including translation, cell trafficking, RNA binding, cell adhesion,
hydrolysis, lipid
metabolism, catabolism, and cellular structure.
[00124] Table 1, below, depicts the twenty most abundant proteins, with proper
names,
enriched in the intestine of adult female B. malayi based on normalized
spectral abundance
factor (NSAF). The NSAF enrichment values are also depicted. "Specific" means
that the
protein was only found within the intestine.
TABLE 1
32
CA 02979840 2017-09-14
WO 2016/149460 PCT/US2016/022787
Abundance """'SiSAV"'
NSAF
enrichment
RiProtein Type Accession Name Intestine
Intesting
Translational Bml 41515 40S ribosomal protein S21, putative 5.4E-03
2.17
Muscle Calsequestrin, skeletal muscle
Associated Bml 28910 isoform precursor, putative 2.5E-03
2.90
Cell trafficking Bml 14235 SNARE domain containing protein 2.4E-03
2.0
Muscle Probable myosin regulatory light
Associated Bml 45035 chain, putative 2.2E-03
2.5
aspartic protease BmAsp-1,
Protease Bml 34740 identical 1.1E-03
16.0
carrier protein Bml 21135 Acyl CoA binding protein 9.0E-04
7.68
Muscle myosin heavy chain, nonmuscle
Associated Bml 00655 type 1, putative 7.8E-04
2.0
Phagocytosis
associated Bml 02265 MGC69076 protein-related 7.3E-04
3.77
Xenobiotic UDP-glucoronosyl and UDP-
metab oli sm Bml 13480 glucosyl transferase family protein 7.0E-04
28.16
Glycine-rich RNA-binding protein.-
RNA binding Bml 20295 related 6.9E-04
8.96
Miscellaneous Bm1 25280 Prion-like--related 6.4E-04
2.37
Cell Adhesion Bml 10500 AMOP domain containing protein 6.1E-04
5.99
Histidine acid phosphatase family
Hydrolase Bml 24820 protein 6.1E-04
6.32
Cytoskeleton Bml 30265 Tubulin alpha chain, putative 5.9E-04
2.95
Excitatory amino acid transporter,
Transporter Bml 42930 putative 5.7E-04
2.75
Lipid NAD-dependent malic enzyme,
Metabolism Bml 08150 mitochondrial precursor, putative 5.5E-04
7.10
Catabolism Bml 48185 putative amidase 5.1E-04
3.74
Major Facilitator Superfamily
Transporter Bml 24840 protein 4.7E-04
19.88
Papain family cysteine protease
Protease Bml 18805 containing protein 4.4E-04
Specific
Protease Bml 00205 ShTK domain containing protein 4.2E-04
3.42
Many predominant body wall enriched proteins provide muscular structure or are
involved in muscular contraction
[00125] The body wall of B. malayi includes, from superficial to deep, the
epicuticle, cuticle,
epidermis, musculature (divided into a superficial fibrous portion and a
deeper metabolically
active portion) and the lateral cords (FIG. 4). The musculature is separated
into quadrants by
the lateral, ventral and dorsal cords with up to 9 myocytes per quadrant
(Vincent et al., 1975,
33
CA 02979840 2017-09-14
WO 2016/149460 PCT/US2016/022787
J. Parasitol., 61, 499-512.). The lateral cords contain the cell bodies of the
epidermis, which
produces and maintains the cuticle. Also associated with the lateral cords is
a secretory gland
which is connected to the secretory pore by the secretory canal (Landmann et
al., 2010, PLoS
Negl. Trop. Dis., 4, e758) herein incorporated by reference. The ventral and
dorsal cords are
associated with nerves that innervate the musculature.
[00126] GSEA of the body wall showed a bias for cytoskeletal proteins and
proteins of
immunological interest to be present within the body wall (FIG. 5). Further,
analysis of the
20 most abundant named proteins that were enriched within the body wall by
NSAF yielded
12 proteins associated with muscle structure or regulation of muscular
contraction (Table 2).
These included an actin (Bml 21705), 4 myosins (Bml 40715, Bml 50805, Bml
00935,
Bml 14060), 2 paramyosins (Bml 04450, Bml 02615), 1 tropomyosin (Bml 02060),
and a
disorganized muscle protein (Bml 40320). In addition to the muscular proteins,
there were 3
cuticular proteins, a glutathione peroxidase, which provides protection from
oxidative
damage, a cytoskeletal protein, a heat shock protein, and a glutamine
synthetase.
[00127] Table 2, below, depicts the twenty most abundant proteins enriched in
the body wall
of adult female Brugia malayi.
TABLE 2
Abundance NSAF
(NSAF)
enrichment
Protein type Accession Name Body Wall Body Wall
Muscle 6.2E-02
3.86
associated Bml 21705 actin 1, putative
2.0E-02 2.94
Cytoskeletal Bml 45215 intermediate filament protein, putative
Muscle Disorganized muscle protein 1, 1.6E-02
5.15
associated Bml 40320 putative
1.4E-02 7.97
HSP Bml 19805 small heat shock protein, putative
Muscle 1.1E-02
5.87
associated Bm1 04450 Paramyosin, putative
Muscle 1.0E-02
6.33
associated Bml 02615 Paramyosin, identical
Calcium 6.5E-03
9.81
Binding Bml 48810 EF hand family protein
Nematode cuticle collagen N-terminal 6.1E-03
3.05
Cuticle Bml 13015 domain containing protein
Muscle 6.0E-03
5.24
associated Bml 01235 Tropomyosin-related
5.9E-03 3.31
Muscle Bml 49075 Calponin homolog OV9M, putative
34
CA 02979840 2017-09-14
WO 2016/149460 PCT/US2016/022787
Associated
Muscle 5.8E-03
3.11
associated Bml 40715 myosin heavy chain, putative
Nematode cuticle collagen N-terminal 5.5E-03
6.57
Cuticle Bml 54705 domain containing protein
Muscle 4.7E-03
4.00
associated Bml 50805 Myosin tail family protein
Cuticular glutathione peroxidase 4.5E-03
2.59
Antioxidant Bml 40465 precursor, putative
Muscle myosin heavy chain B (WIC B), 4.4E-03
3.36
associated Bml 00935 putative
Carbohydrate 4.2E-03
2.67
metabolism Bm1 16060 carbohydrate phosphorylase, putative
Muscle myosin heavy chain B (WIC B), 4.1E-03
2.23
associated Bml 14060 putative
Nematode cuticle collagen N-terminal 3.2E-03
2.40
Cuticle Bml 17485 domain containing protein
Muscle 3.2E-03
3.19
associated Bml 02060 Tropomyosin family protein
Amino Acid 3.0E-03
3.16
Synthesis Bml 53470 glutamine synthetase, putative
Nuclear regulatory proteins, including those involved in chromatin
organization are
enriched and highly abundant in the reproductive tract
[00128] The nematode female reproductive tract consists of two ovaries where
gamete
production takes place, two seminal receptacles (aka spermatheca) which store
sperm
obtained from males, and 2 uterine tubes that allow for embryo and subsequent
in utero
microfilaria development (FIG. 1). The two uterine tubes merge into the vulva,
which is on
the ventral surface of the worm in the cephalic region (Fischer et al., 2011,
PLoS Negl. Trop.
Dis., 5, e1174. Jiang et al., 2012, Int. J. Parasitol., 42, 841-850, Landmann,
et al., 2010, Li et
al., 2012, BMC Genomics, 13, 184, which are herein incorporated by reference
in their
entireties). GSEA showed a bias for transcription and nuclear regulation
proteins to be
present within the female reproductive tract (FIG. 6). Similarly the 20 most
abundant named
proteins that were enriched in the reproductive tract as assessed by NSAF
contained many
proteins involved in nuclear regulation. 12 proteins contained domains
associated with
nucleotide binding or splicing, with 8 of these 12 being histones or histone
linkers
(Bml 02505, Bml 02515, Bml 20280, Bml 02495, Bml, 20285, Bml, 38685,
Bml 02800, Bml 04110). Three microfilarial sheath proteins were also abundant
and
enriched within the reproductive tract, which is consistent with presence of
developing
CA 02979840 2017-09-14
WO 2016/149460 PCT/US2016/022787
microfilariae within the uterine tubes. The remaining 7 proteins are involved
in trafficking,
protection from oxidation, xenobiotic metabolism, proteolysis and cell
adhesion.
[00129] Table 3, below, depicts the most abundant enriched named proteins in
the
reproductive tract of adult female Brugia malayi. Specific means that the
protein was only
found within the reproductive tract.
TABLE 3
Abundanpo
NSAF Enrichment'
Reproductive Reproductive õ
Pi otel ii Ts pe ti act ti at
Chromatin 3.4E-02
8.1
organization Bml 02505 histone H2A, putative
Chromatin 3.1E-02
2.7
organization Bml 02515 histone H4, putative
Chromatin Probable histone H2B 3, 1.1E-02
4.3
organization Bml 20280 putative
Chromatin 7.8E-03
25.9
organization Bml 02495 histone H3, putative
Major microfilarial sheath 6.2E-03
2.6
Sheath Bml 19100 protein precursor.-related
Chromatin 5.9E-03
17.2
organization Bml 20285 histone H2A, putative
Chromatin 3.4E-03
2.7
organization Bml 38685 Histone H2A variant, putative
2.8E-03
2.9
Sheath Bml 05185 sheath protein 5, identical
peroxisomal membrane 2.2E-03
2.6
Trafficking Bml 07925 anchor protein, putative
Glutathione S-transferase, N-
terminal domain containing 2.0E-03
2.3
Antioxidant Bml 44840 protein
DNA high mobility group protein, 1.7E-03
binding Bml 25620 putative
10.2
microfilarial sheath protein, 1.2E-03
2.4
Sheath Bml 00650 identical
RNA 1.2E-03
2.2
splicing Bm1 49560 NOP5/NOP58, putative
small nuclear
ribonucleoprotein-associated
RNA protein homolog F9F13.90 - 1.1E-03
2.3
modulation Bm1 49460 Arabidopsis thaliana, putative
Chromatin retinoblastoma-binding 1.1E-03
2.6
organization Bml 57630 protein., putative
Chromatin linker histone H1 and H5 9.6E-04
4.7
organization Bml 04110 family protein
36
CA 02979840 2017-09-14
WO 2016/149460 PCT/US2016/022787
Flavin-binding
Xenobiotic monooxygenase-like family 9.4E-04
2.6
metabolism Bml 32235 protein
Chromatin 9.0E-04
Specific
organization Bml 02800 Histone H2B 2, putative
8.9E-04
36.5
Protease Bml 45620 Trypsin family protein
Cell Fasciclin domain containing 8.1E-04
2.8
Adhesion Bml 17270 protein
Identification of potential intestine vaccine candidates
[00130] To identify gastrointestinal proteins that could potentially be used
as vaccine
candidates, we analyzed the proteomics set for proteins that were enriched in
the intestine,
had at least one predicted transmembrane domain, and were not predicted to be
in the
mitochondria. We sought luminal surface proteins because these proteins may be
accessible
to host antibodies after vaccination. 106 proteins were identified with these
criteria (Table A
and Table B, below, provided after the Examples) and were categorized based on
likely
metabolic function within the cell. The amino acid sequences identified by
Genbank
Accession numbers in Table. A and Table B are herein incorporated by
reference.
[00131] In order to evaluate the potential of the 106 surface proteins as pan-
filarial vaccine
candidates, we performed a blast search for each protein against databases for
Homo sapiens,
Wuchereria bancrofti, which causes lymphatic filariasis, Onchocerca volvulus,
which causes
river blindness, L. loa, which causes loiasis, and Dirofilaria immitis, which
causes
heartworm. Proteins were selected that contained a percent identity of >75% to
W. bancrofti
or 0. volvulus and <40% homology to humans. 72 proteins matched these
criteria.
[00132] We then selected those proteins that had 1-2 transmembrane domains for
ease of
recombinant protein production. These were evaluated with Interpro software
for the
presence of non-cytoplasmic domains that could be bound by host antibodies. 27
proteins
matched all of these criteria (Tables C and D, below, provided after the
Examples), with 12
displaying substantial homology between all of the filarial species. Of these
27 proteins, 10
are hypothetical proteins, 3-4 are proteases, 2 are involved in xenobiotic
metabolism using
glucuronidation, 2 participate in cell adhesion, 2 function in cell signaling,
and 2 are
chaperones.
Certain excretory/secretory (ES) products are associated with specific
anatomic
fractions
37
CA 02979840 2017-09-14
WO 2016/149460 PCT/US2016/022787
[00133] 227 proteins were found within the ES product of adult female B.
malayi in a
previous study by Bennuru and colleagues (Bennuru et al., 2009, PLoS Negl.
Trop. Dis., 3,
e410, herein incorporated by reference). To better define the origin of these
proteins, we
analyzed all adult female ES proteins for enrichment within any of the three
worm fractions
from this study. Four (1.7%) of these proteins were either enriched or
specific to the intestine
(Table 4). The most notable of these was the papain family cysteine protease
(Bml 18805).
Eight (3.5%) female ES products were enriched within the body wall (Table 5),
including two
proteins that protect against oxidative damage, cuticular glutathione
peroxidase (Bml 40465)
and peptide methionine sulfoxide reductase (Bml 10795) (Weissbach, et al.,
2005). Other
ES products enriched within the body wall included a cuticle collagen (Bm
13015), and
muscular proteins.
[00134] There were 30 adult female ES products (13%) enriched within the
female
reproductive tract (Table 6). Some of these antigens include Juv-p120 (Bml
18010), which
has been implicated in being critical for MF survival, Von willebrand factor
type A domain
containing protein (Bml 27495), which likely binds to collagen, a trypsin
inhibitor
(Bml 03520), and an aspartyl amino peptidase (Bml 16690).
[00135] Tables 4, 5, and 6 below depict the intestine-enriched, body-wall
enriched, and
reproductive tract-enriched ES products, respectively. "Specific" means that
the protein was
only was only identified within the specified anatomical fraction.
38
CA 02979840 2017-09-14
WO 2016/149460 PCT/US2016/022787
TABLE 4
Abundance (NSAF) Enrichment1D Name Body wall
Body wall
Nematode cuticle collagen N- 6.1E-03
3.05
Bml 13015 terminal domain containing protein
4.7E-03 4.00
Bml 50805 Myosin tail family protein
Cuticular glutathione peroxidase 4.5E-03
2.59
Bml 40465 precursor, putative
8.8E-04 7.42
Bml 39425 protein unc-22, putative
8.0E-04 4.73
Bml 26690 Prion-like-, putative
Immunoglobulin I-set domain 4.5E-04
7.68
Bml 12515 containing protein
Ryanodine Receptor TM 4-6 family 1.4E-04
3.67
Bml 45145 protein
Peptide methionine sulfoxide 9.6E-05
Specific
Bml 10795 reductase family protein
TABLE 5
Abundance (NSAF) Enrichment
ICY Name õBoth wall Both wall
Nematode cuticle collagen N- 6.1E-03
3.05
Bm1 13015 terminal domain containing protein
4.7E-03
4.00
Bml 50805 Myosin tail family protein
Cuticular glutathione peroxidase 4.5E-03
2.59
Bml 40465 precursor, putative
8.8E-04
7.42
Bml 39425 protein unc-22, putative
8.0E-04
4.73
Bm1 26690 Prion-like-, putative
Immunoglobulin I-set domain 4.5E-04
7.68
Bml 12515 containing protein
Ryanodine Receptor TM 4-6 family 1.4E-04
3.67
Bml 45145 protein
Peptide methionine sulfoxide 9.6E-05
Specific
Bml 10795 reductase family protein
39
CA 02979840 2017-09-14
WO 2016/149460 PCT/US2016/022787
TABLE 6
Abundance NSAP
= .== .==
(NSAF) =-= Enrichment
= Reproductive Reproductive
Tract . Tract,
Bml 29260 60S ribosomal protein L34, putative 4.6E-04 2.4
Biotin/lipoate A/B protein ligase family
Bml 20440 protein 4.5E-04 2.8
Bml 43080 hypothetical protein 3.7E-04 2.1
Potential global transcription activator
Bml 02485 SNF2L, putative 2.5E-04 2.6
Bml 16970 hypothetical protein 1.8E-04 2.7
Bml 16690 Aspartyl aminopeptidase, putative 1.6E-04 3.4
excretory/secretory protein Juv-p120
Bml 18010 precursor-related 1.4E-04 3.4
Bml 21390 RNA binding protein, putative 1.3E-04 2.0
Bml 48000 RAS FAMILY PROTEIN 1.1E-04 2.7
Bml 12225 G-patch domain containing protein 1.0E-04 3.9
Kunitz/Bovine pancreatic trypsin inhibitor
Bml 03520 domain containing protein 9.9E-05 2.8
Bml 02770 Galactosyltransferase family protein 8.5E-05 2.6
Bml 48025 Alpha-catulin, putative 7.5E-05 3.5
Gex interacting protein protein 4, isoform c-
Bm1 41495 related 7.2E-05 7.0
Bml 18480 HYPOTHETICAL PROTEIN 7.2E-05
Specific
26S PROTEASOME REGULATORY
Bml 46460 CHAIN 4, PUTATIVE 6.4E-05 5.4
tRNA modification GTPase TrmE family
Bml 49790 protein 5.1E-05 2.0
von Willebrand factor type A domain
Bml 27495 containing protein 4.9E-05 2.1
Bml 46930 HYPOTHETICAL PROTEIN 4.4E-05 2.1
Bml 21025 hypothetical protein, conserved 4.3E-05 3.4
Bml 25670 hypothetical protein 4.0E-05
Specific
Bml 41650 hypothetical protein 3.2E-05 4.1
Bml 54890 RNA recognition motif 3.0E-05 2.0
Bml 16685 hypothetical protein 2.7E-05 2.7
Phosphatidylinositol 3- and 4-kinase family
Bml 40395 protein 2.6E-05 4.3
Bml 00750 RhoGEF domain containing protein 1.9E-05 3.4
Formin Homology 2 Domain containing
Bml 25450 protein 1.8E-05
Specific
HYPOTHETICAL PROTEIN,
Bm1 05305 CONSERVED 1.7E-05
Specific
Bml 42420 Eye-specific diacylglycerol kinase, putative 1.6E-05
Specific
CA 02979840 2017-09-14
WO 2016/149460 PCT/US2016/022787
Bml 17115 conserved hypothetical protein 9.8E-06
Specific
Summary of the Results
[00136] In conclusion, the results detail the proteins found within the major
anatomic
fractions of B. malayi, including the intestine, body wall, and reproductive
tract. The results
suggest that the intestine of adult filarial worms likely plays an important
role in digestion
and absorption, and may have other physiologic functions that have not yet
been
characterized. Further, we have identified vaccine candidates from the B.
malayi intestine
that that could be protective against all major filarial pathogens of humans,
and which may
provide protective efficacy as vaccines against the causative agents of
lymphatic filariasis,
river blindness, loiasis as well as heartworm.
Sequences
[00137] The sequence identifiers described herein and the sequences set forth
in the
following sequence listing correspond to the Accession numbers and
descriptions described
in Table 7, below.
TABLE 7
SEQ ID Gene Symbol and Protein Type Description
NO:
Cell Adhesion
1 XP 001899381 Bml 39630 Immunoglobulin I-set
domain containing
protein
2 XP 001892066 Bml 02820 EGF-like domain
containing protein
Cell Signaling
3 XP 001897556 Bm1 30585 Tyrosine-protein kinase
abl-1.-related
4 XP 001895334 Bml 19395 Protein kinase domain
containing protein
XP 001899110 Bml 38285 Ser/Thr protein
phosphatase family
protein
Chaperone/HSP
6 XP 001894589 Bml 15660 DnaJ domain containing
protein
7 XP 001895946 Bml 22450 hemimethylated DNA
binding domain
containing protein
41
CA 02979840 2017-09-14
WO 2016/149460 PCT/US2016/022787
Glycosylation/glucuronidation
8 XP 001900394 Bml 44655 Fukutin.-related
9 XP 001894161 Bml 13480 UDP-glucoronosyl and
UDP-glucosyl transferase
family protein
Miscellaneous
XP 001901384 Bml 49590 CG3054-PA-related
11 XP 001893572 Bml 10500 AMOP domain
containing protein
12 XP 001901064 Bml 48010 EGF-like domain
containing protein
Proteases
13 )CP 001899113 Bml 38300 Peptidase family M1
containing protein
14 XP 001893672 Bml 11005 MGC84665 protein-
related
XP 001902078 Bml 53050 Reprolysin
Possible Proteases
16 XP 001891567 Bml 00205 ShTK domain containing
protein
Protease Inhibitors
17 XP 001893428.1 Bm1 09775 "serpin, putative"
Hypothetical Proteins
18 XP 001901910 Bml 52210 hypothetical protein
19 XP 001902925 Bml 57335 "Conserved hypothetical
protein, putative"
XP 001895546 Bml 20460 hypothetical protein
21 XP 001900482 Bml 45100 hypothetical protein
22 XP 001893045 Bml 07875 CONSERVED
HYPOTHETICAL
PROTEIN
23 XP 001894967 Bml 17550 hypothetical protein
24 XP 001893039 Bml 07845 hypothetical protein
XP 001894908 Bml 17255 hypothetical protein
26 XP 001895519 Bml 20325 Hypothetical protein-
conserved
27 XP 001900708 Bml 46230 hypothetical protein
42
TABLE A 0
BLAST-P OF INTESTINE ENRICHED NON-MITOCHONDRIAL PROTEINS WITH TRANSMEMBRANE
DOMAINS AGAINST W.
BANCROFTI, 0. VOLVULUS AND H. SAPIENS
B. malayi H. sapiens W.
bancrofti 0. volvulus
Protein Type Gene
Symbol/ Accession Query
Query Query
No./GI No. Description %Ident* cov.**
%Ident* Cov** %Ident* Cov**
Acyltransferase
Bml 43465/
XP 001900154.1/
GI: 170590790 Temporarily assigned gene name protein 40,
putative xx xx 93
290-882 79 50-878
Carbohydrate Metabolism
Bm1 36055/
XP 001898658.1/
GI: 170587792
hexokinase, putative 47 16-437 65
22-438 82 1-439
Bml 52335/
XP 001901935.1/ UDP-N-acetylglucosamine-dolichyl-
GI: 170594367 phosphate N-
acetylglucosaminephosphotransferase,
putative 49 2-404 94
1-406 89 1-406
Catabolism
1-d
Bml 48180/
XP 001901098.1/
GI: 170592691
Amidase family protein 41 45-303 96
90-324 75 1-373
Cell Adhesion
*%Ident" is the percentage of amino acids within the query coverage identical
to query sequence.
**Query coy." span of amino acids in the query sequence that aligns with the
target sequence producing significant alignment
TABLE A (CONTINUED)
0
t.)
Bm 1 39630/
o
1-,
c:
XP 001899381.1/
.6.
GI:170589239
.6.
c:
Immunoglobulin I-set domain containing
o
protein 28 45-1170
97 628-1171 87 26-1171
Bml 02820/
XP 001892066.1/
GI:170572325
EGF-like domain containing protein 35 53-206
96 1-269 82 3-269
Cell Signaling
Bml 30585/
P
XP 001897556.1/
..,
4, GI: 170585572
=
o.
4=,
o
Iv
o
Tyrosine-protein kinase abl-1.-related 24 212-281
95 10-281 79 10-281 ,
..,
,
Bm 1 19395/
.
,
,
XP 001895334.1/
.
GI:170580602
Protein kinase domain containing protein 34 15-1280
98 1-681 92 1-1280
Bml 38285/
XP 001899110.1/
GI: 170588697 Ser/Thr protein phosphatase family
Iv
n
protein 40 22-287
95 9-293 79 2-293
Bml 51260/
cp
t.)
XP 001901720.1/
1-,
GI: 170593937
c:
'a
Innexin family protein 29 327-399
83 1-523 64 1-533 t.)
t.)
--.1
oe
--.1
TABLE A (CONTINUED)
0
t..)
Bml 31730/
o
1¨
o,
XP 001897792.1/
1¨
.6.
GI:170586046 phosphatidate cytidylyltransferase-
vD
.6.
related 27 56-
127 97 1-128 84 1-118 o,
o
Bml 36290/
XP 001898705.1/
GI:170587887 Putative phosphatidate
cytidylyltransferase, putative 50 41-
480 94 1-374 85 5-487
Bml 43990/
XP 001900260.1/
GI:170591002
Latrophilin receptor protein 2, putative 42 354-
715 81 59-873 68 32-873 p
Brill 05960/
2
XP 001892664.1/
-
.3
.6.
.
vi GI:170574085
r.,
Patched family protein 20 229-
896 96 66-549 73 1-933
,
_.]
Brill 23705/
,
o
,
XP 001896198.1/
,
GI:170582592 protein C24B5.3 ,putative 21 8-
957 32 12-955 83 2-746
Bm 1 39815/
XP 001899418.1/
GI:170589313 Ly-6-related protein HOT-2-related 29
18-55 95 97-199 89 60-199
Bml 55745/
XP 001902606.1/
GI:170596018 sulfakinin receptor protein, putative 28
5-333 86 1-299 71 1-398 1-d
n
Bm 1 54240/
XP 001902307.1/ Endonuclease/Exonuclease/phosphatase
cp
GI:170595251 family protein 38 3-
298 98 1-205 85 1-391 t..)
o
1¨
c.,
7:-:--,
t..,
t..,
-4
oe
-4
TABLE A (CONTINUED)
Bm1 52975/
0
t.)
XP 001902063.1/ ER lumen protein retaining
1-,
c:
GI:170594623 receptor, putative 69 1-
207 99 1-213 96 1-213
.6.
Bml 48590/ Low-density lipoprotein
.6.
XP 001901181.1/ receptor domain class A
c:
o
GI:170592857 containing protein 47 4-
46 91 1-154 66 1-154
Cellular Trafficking
Bm1 14235/
XP 001894314.1/ SNARE domain containing
GI:170578208 protein 37 9-
230 98 1-248 86 1-248
P
Chaperone/HSP
2
Bm1 15660/
.3'
.6.
.
c: XP 001894589.1/ DnaJ domain containing
.
GI:170578901 protein 27 25-
835 91 1-839 77 3-839
o
,
..,
Bm1 22450/ hemimethylated DNA
XP 001895946.1/ binding domain containing
,
,
GI:170582031 protein 25 34-
112 97 29-119 95 29-119
DNA/RNA Binding
Bm1 41070/ Zinc finger DHEIC domain
XP 001899675.1/ containing protein 5,
GI:170589828 putative 53 11-
262 97 1-445 86 1-444
Glycosylation/glucuronidation
Iv
n
,¨i
cp
t..,
=
c7,
-c-:--,
t..,
t..,
-4
oe
-4
TABLE A (CONTINUED)
Bml 34610/
0
t..)
XP 001898369.1/
1-,
GI:170587206 glycosyl transferase, group 2 family
o
1-,
protein 56 80-554
96 1-447 88 1-582 .6.
o
.6.
Bm1 44655/
o
o
XP 001900394.1/
GI:170591272 Fukutin.-related 31 138-364
96 1-362 73 1-364
Bml 13480/
XP 001894161.1/ UDP-glucoronosyl and UDP-glucosyl
GI:170577851 transferase family protein 27 35-509
95 1-425 29 214-293
Immunological
Bml 50985/
XP 001901665.1/
Complement component C6 precursor.- P
c,
GI:170593827 related 32 49-136
98 1-171 72 3-161 "
_.,
.6. Miscellaneous
--4
.
Bml 15480/
N,
XP 001894556.1/
_.,
,
c,
GI:170578816 Acyltransferase family protein 28 295-
352 94 44-351 80 17-649 '
,
,-,
Bml 23850/
.
XP 001896227.1/
GI:170582654 cDNA sequence BC017158-related 37 38-384
93 163-353 81 1-389
Bm1 49590/
XP 001901384.1/
GI:170593263 CG3054-PA-related 28 97-260
81 1-242 69 1-260
Bml 15855/
1-d
XP 001894628.1/
n
,-i
GI:170578992 D4Ertd196e protein, putative 56 14-174
94 1-177 81 1-150
cp
t..)
o
1-,
c.,
-a-,
t..,
t..,
-4
oe
-4
TABLE A (CONTINUED)
Bm1 10500/
0
t.)
XP 001894628.1/
1-,
GI:170578992 AMOP domain containing protein 26 652-
932 98 679-1377 92 1-1513 c:
1-,
.6.
Bm1 06760/
.6.
XP 001892822.1/
c:
o
GI:170574457 zgc: 100814 protein-
related 39 9-355 95 1-136 75 1-356
Bml 41280/
XP 001899713.1/ uncharacterized hypothalamus protein
GI:170589904 HTMP, putative 56 50-
295 96 1-296 82 4-296
Bml 17180/
XP 001894893.1/ MiaB-like tRNA modifying enzyme,
GI:170579583 archaeal-type family
protein 56 1-402 97 17-256 90 1-424
Bml 48010/
p
XP 001901064.1/
2
GI:170592623 EGF-like domain containing protein 36
10-395 91 19-338 66 6-560
.3'
.6.
.
oe
.
Proteases
Bml 18805/
,
,
,
XP 001895218.1/
Papain family cysteine protease containing .
,
GI:170580338 protein 34 65-
309 68 73-267 52 35-309 ,
Bml 38300/
XP 001899113.1/
GI:170588703 Peptidase family M1 containing protein 28
136-586 90 90-819 67 1-819
Bm1 26370/
XP 001896728.1/
GI:170583765 Rhomboid family protein
36 77-347 96 1-377 83 1-377
Bml 11005/
Iv
n
XP 001896728.1/
GI:170583765 MGC84665 protein-related
38 2-98 95 1-96 80 1-98 cp
t.)
o
1-,
c:
'a
t.)
t.)
--.1
oe
--.1
TABLE A (CONTINUED)
0
t..)
o
1-,
Bml 53050/
c:
1-,
XP 001902078.1/
.6.
vD
.6.
GI:170594653 Reprolysin 32 153-753
91 96-845 77 1-839 c:
o
Possible Protease
Bml 00205/
XP 001891567.1/
GI:170571016 ShTK domain containing protein 27 54-161
80 142-229 52 70-227
Protease inhibitor
Bml 09775/
XP 001893428.1/
GI:170575897 serpin, putative 29 26-388
75 84-375 52 29-390 P
N,
Sterol Metabolism
'
,
.6. Bm1 37660/
.3
vD
.
XP 001898982.1/
"
,
GI:170588441 Oxysterol-binding protein 45 37-747
93 312-748 87 57-724 -,
,
,
Structural
,
Bm1 53475/
XP 001902163.1/ Nematode cuticle collagen N-terminal
GI:170594883 domain containing protein 40 102-274
85 48-288 61 1-291
Bml 04695/
XP 001892417.1/
GI:170573305 Cuticle collagen F09G8.6.-related 40
80-251 96 43-270 89 1-266
Bm1 19730/
Iv
XP 001895401.1/ Autophagy protein Apg9 containing
n
,-i
GI:170580769 protein 43 50-655
91 204-814 82 1-814
cp
t..)
Transporters
o
1-
o
-a-,
t..,
t..,
-4
oe
-4
TABLE A (CONTINUED)
Brill 08720/
0
t.)
XP 001893214.1/
1¨,
GI:170575377 ABC
transporter N-terminus family protein 46 65-153 94 1-150 78 1-
153 c:
1¨,
.6.
Bm 1 06830/
.6.
XP 001892835.1/
ABC transporter transmembrane region c:
o
GI:170574488 family protein 40 80-246
92 82-183 60 1-248
Bm 1 08185/
XP 001893108.1/
GI:170575121 Cation transporter family protein 37
35-439 96 1-444 84 3-444
Bml 34425/
XP 001898332.1/
GI:170587131 Ctr copper transporter family protein 28
63-255 89 1-276 69 10-276
Brill 00795/
p
XP 001891680.1/
2
GI:170571314 E1-E2 ATPase family protein 49 6-523
96 1-449 87 1-530
.3'
vi
.
= Brill 42365/
r.,
XP 001899937.1/
,2
..,
GI:170590354 ZIP Zinc transporter family protein 25
17-386 92 1-387 76 1-387 ,
o
,
Brill 40010/
,
XP 001899457.1/ NRAMP-like transporter Kl1G12.4,
GI:170589391 putative 59 44-457
100 228-457 85 34-457
Bm 1 38955/
XP 001899244.1/ Twik family of potassium channels protein
GI:170588965 28, putative 24 101-
536 93 1-561 96 49-561
Bml 44770/
XP 001900417.1/
TWiK family of potassium channels Iv
n
GI:170591318 protein 7, putative 26 136-
438 98 80-330 87 1-525
cp
t.)
o
1¨,
c:
'a
t.)
t.)
--.1
oe
--.1
TABLE A (CONTINUED)
Bm1 24840/
0
t.)
XP 001896428.1/
1-,
GI:170583097 Major Facilitator Superfamily protein 27
7-477 95 102-493 85 1-493 c:
1-,
.6.
Bml 37140/
.6.
XP 001898875.1/
c:
o
GI:170588227 Major Facilitator Superfamily protein 34
70-221 90 100-739 69 1-739
Bm1 24985/
XP 001896457.1/
GI:170583158 cation efflux family protein 26 181-
300 97 54-483 80 15-483
Bm1 46360/
XP 001900734.1/ Transmembrane amino acid transporter
GI:170591953 protein 27 29-447
97 32-443 93 1-401
Bm1 25200/
p
XP 001896499.1/
2
GI:170583257 Mitochondria' carrier C16C10.1, putative 47
12-332 97 1-332 84 1-332
.3'
vi
1-, Bm1 01695/
r.,
XP 001891855.1/
,2
..,
GI:170571765 RE11181p-related 28 14-258
89 1-360 22 1-258 ,
o
,
Bm1 42075/
,
XP 001899877.1/
GI:170590234 zgc:92765, putative 49 11-351
81 1-397 80 1-396
Bml 43555/ ABC TRANSPORTER
XP 001900172.1/
TRANSMEMBRANE REGION FAMILY 549-
GI:170590826 PROTEIN 40 19-1536
91 78-1087 71 1536
Bm1 37475/
XP 001898945.1/
Iv
n
GI:170588367 Major Facilitator Superfamily protein 33
100-320 93 67-806 76 1-791
cp
t.)
o
1-,
c:
'a
t.)
t.)
--.1
oe
--.1
TABLE A (CONTINUED)
Bml 38360/
0
t..)
XP 001899125.1/
1¨
GI:170588727 major facilitator
superfamily protein 30 41-553 98 31-565 92 31-564
o
1¨
.6.
Bm1 15490/
o
.6.
XP 001894558.1/
o
o
GI:170578824 ABC transporter family protein 45 67-
706 98 35-543 81 4-712
Bml 31305/
XP 001897706.1/ vesicular acetylcholine transporter unc-17,
GI:170585872 putative 50 17-
440 94 20-528 91 1-528
Bm1 42930/
XP 001900048.1/
GI:170590576 Excitatory amino acid transporter, putative
59 7-469 98 1-320 92 245-498
Bm1 02560/
p
XP 001892014.1/
GI:170572178 Sodium/calcium
exchanger protein 35 29-341 86 156-342 78 1-342
.3
t..) Bml 31865/
r.,
XP 001897818.1/
Probable calcium-binding mitochondrial .
,
_.]
GI:170586099 carrier F55A11.4, putative 45 46-
504 93 5-508 86 4-506 ,
o
,
,
Hypothetical Proteins
.
Binl 04935/
XP 001892465.1/
GI:170573424 hypothetical protein 47 4-37
28 1-54 65 1-68
Bm1 33605/
XP 001898167.1/
GI:170586800 hypothetical protein 41 42-
70 81 1-216 49 58-216
Bm1 34095/
1-d
n
XP 001898267.1/
GI:170587000 hypothetical protein 29 15-
88 42 55-87 68 1-131 cp
t..)
Bm1 22820/
o
1¨
o
XP 001896020.1/
t..)
GI:170582194/ hypothetical protein 35 30-
69 100 1-68 94 1-81 t..)
--.1
oe
--.1
TABLE A (CONTINUED)
Bm1 26845/
0
t..)
XP 001896819.1/
1¨
GI:170584006 Hypothetical protein 33 77-164
92 1-162 79 58-245 o
1¨
.6.
Bm1 45625/
o
.6.
XP 001900588.1/
o
o
GI:170591660 hypothetical protein 38 127-171
90 1-338 76 25-334
Bml 52210/
XP 001901910.1/
GI:170594317 hypothetical protein 29 238-350
97 53-433 85 1-431
Bml 02860 hypothetical protein xx xx
33 11-31 38 11-31
Bml 57335/
XP 001902925.1/
GI:170596866/ Conserved hypothetical protein, putative 31
114-236 96 1-246 89 1-246 P
Bm1 25895/
"
_.]
XP 001896638.1/
vi
.
GI:170583561 hypothetical protein 28 115-179
96 122-325 68 33-325 .
.,
Bm1 26820/
,
_.]
,
XP 001896814.1/
.
,
GI:170583994 hypothetical protein 38 318-378
88 1-317 59 1-191 ,
Bm1 46300/
XP 001900722.1/
GI:170591929 hypothetical protein, conserved 38
129-154 91 195-387 52 30-387
Bml 20460/
XP 001895546.1/
GI:170581122 hypothetical protein 30 103-147
24 94-147 82 1-191
Bm1 27875/
1-d
n
XP 001897026.1/
GI:170584478 hypothetical protein 28 186-237
91 61-298 76 12-202 cp
t..)
Bm1 30935/
1¨
o
XP 001897629.1/
t..)
GI:170585718 hypothetical protein 39 37-67
82 4-90 27 30-89 t.)
--.1
oe
--.1
TABLE A (CONTINUED)
Bm1 53700/
0
t..)
XP 001902205.1/
1¨
GI:170594994 hypothetical protein 37 56-108
92 178-216 56 1-220 o
1¨
.6.
Bm1 57235/
o
.6.
XP 001902905.1/
o
o
GI:170596815 hypothetical protein 40 39-81
50 45-62 65 1-67
Bm1 45100/
XP 001900482.1/
75-
GI:170591448 hypothetical protein 29 330-
414 85 118-727 60 727
Bm1 07875/
XP 001893045.1/
CONSERVED HYPOTHETICAL 53-
GI:170574981 PROTEIN 31 84-225
99 142-231 85 231
Bml 30410/
p
XP 001897520.1/
105-
GI:170585498 conserved hypothetical protein 38 152-
201 99 112-234 89 234
.3
vi
.
.6. Bml 17550/
r.,
XP 001894967.1/
82-
_.]
GI:170579749 hypothetical protein 33 63-121
87 77-129 82 125 ,
o
,
Bm1 00920/
,
XP 001891702.1/ Hypothetical 30.5 kDa protein ZK1321.3 in
GI:170571368 chromosome II.-related 25 5-168
93 1-176 72 1-176
Bm1 04875/
XP 001892453.1/
GI:170573392 hypothetical protein xx xx
xx xx xx xx
Bm1 29435/
XP 001897329.1/
23- 1-d
n
GI:170585108 Hypothetical protein 30 23-163
96 23-204 83 204
cp
t..)
o
1¨
c.,
-c-,--,
,-,
,-,
-4
c,
-4
TABLE A (CONTINUED)
Bm1 42465/
0
t..)
XP 001899956.1/
1¨
GI:170590392 hypothetical protein 28 85-134
84 1-394 70 1-394 o,
1¨
.6.
Bm1 48705/
vD
.6.
XP 001901204.1/
o,
o
GI:170592903 conserved hypothetical protein 23 57-
267 97 96-267 74 1-268
Bml 32415/
XP 001897928.1/ Hypothetical 21.5 kDa protein in SEC15-
GI:170586322 SAP4 intergenic region.-related 52
25-168 93 1-176 90 1-176
Bml 07845/
XP 001893039.1/
GI:170574965 hypothetical protein 28 24-108
89 1-210 64 1-210
Bml 15300/
p
XP 001894520.1/
GI:170578730 Hypothetical protein xx xx
xx xx xx xx ,
.3
vi
.
vi Bm1 17255/
r.,
XP 001894908.1/
28-
,
GI:170579615 hypothetical protein 21 93-246
87 17-251 78 251 ,
o
,
Bm1 18965/
,
XP 001895250.1/
GI:170580404 Hypothetical protein 45 46-235
91 1-206 78 1-236
Bml 20325/
XP 001895519.1/
GI:170581054 Hypothetical protein-conserved 37 2-
215 96 1-487 89 1-487
Bm1 44010/
XP 001900264.1/
74- 1-d
n
GI:170591010 hypothetical protein 42 3-33
92 91-185 26 156
Bm1 46230/
cp
XP 001900708.1/
t..)
o
1¨
GI:170591901 hypothetical protein 29 184-256
91 24-278 62 1-278
7:-,--,
,-,
,-,
-4
c,
-4
TABLE B
BLAST P OF THE TABLE A INTESTINE PROTEINS AGAINST L. LOA AND D. IMMITIS.
0
tµ.)
B. malayi L. loa
D. immitis
Protein Type
Gene Symbol/
Accession No./GI Query
Query
No. Description %Ident*
Cov** %Ident* Cov**
Acyltransferase
Bm1 43465/
XP 001900154.1/
GI: 170590790 Temporarily assigned gene name protein
40, putative 88 50-
664 84 64-882
Carbohydrate Metabolism
Bm1 36055/
XP 001898658.1/
GI: 170587792
hexokinase, putative 63 22-
438 84 1-439 .7
Bm1 52335/
XP 001901935 .1/ UDP -N-acetylgluco samine -dolichyl-
GI: 170594367 phosphate N-
acetylglucosaminephosphotransferase,
putative 91 1-
406 87 1-388
Catabolism
Bm1 48180/
XP 001901098.1/
GI: 170592691
Amidase family protein 78 1-
373 74 90-373
Cell Adhesion
*%Ident" is the percentage of amino acids within the query coverage identical
to query sequence.
**Query coy." span of amino acids in the query sequence that aligns with the
target sequence producing significant alignment
oe
TABLE B (CONTINUED)
Btu' 39630/
0
XP 001899381.1/
GI:170589239
Immunoglobulin I-set domain containing
protein 89 1-1171
82 1-1171
Bml 02820/
XP 001892066.1/
GI:170572325
EGF-like domain containing protein 89 62-269
79 2-269
Cell Signaling
Bml 30585/
XP 001897556.1/
GI: 170585572
Tyrosine-protein kinase abl-1.-related 83 10-281
84 10-281
Btu' 19395/
XP 001895334.1/
GI:170580602
Protein kinase domain containing protein 95 1-1280
93 1-1280
Bml 38285/
XP 001899110.1/
GI: 170588697
Ser/Thr protein phosphatase family protein 88 9-293
79 1-290
Bml 51260/
XP 001901720.1/
GI: 170593937
Innexin family protein 69 1-523
64 1-532
oe
TABLE B (CONTINUED)
0
t..)
o
1¨,
c,
Bml 31730/
1¨
.6.
XP 001897792.1/
o
.6.
GI:170586046
o
o
phosphatidate cytidylyltransferase-related 93
1-125 87 1-125
Bml 36290/ Putative phosphatidate
cytidylyltransferase,
XP 001898705.1/ putative
GI:170587887 89
5-487 78 1-487
Bml 43990/
XP 001900260.1/
GI:170591002
Q
Latrophilin receptor protein 2, putative 76
19-841 69 27-873 2
_.]
Bm 1 05960/
'
oe XP 001892664.1/
'
r.,
GI:170574085
.
,
_.]
Patched family protein 87
1-934 75 1-933 ,
o
,
Bm 1 23705/
,
XP 001896198.1/
GI:170582592 protein C24B5.3 ,putative 90
1-934 93 648-959
Bml 39815/
XP 001899418.1/
GI:170589313 Ly-6-related protein HOT-2-related 89
69-199 89 6-189
Bml 55745/
XP 001902606.1/
1-d
n
GI:170596018 sulfakinin receptor protein, putative
36 4-333 64 139-392
Bml 54240/
cp
t..)
XP 001902307.1/ Endonuclease/Exonuclease/phosphatase
=
1¨
GI:170595251 family protein 88
1-256 83 1-391
7:-:--,
Bm 1 52975/
t..)
t..)
--.1
XP 001902063.1/ ER lumen protein retaining receptor,
oe
--.1
GI:170594623 putative 96
1-213 96 1-209
TABLE B (CONTINUED)
0
Bm 1 48590/
XP 001901181.1/ Low-density lipoprotein receptor domain
GI:170592857 class A containing protein 74 4-154 67
9-154
Cellular Trafficking
Bml 14235/
XP 001894314.1/
GI:170578208 SNARE domain containing protein 94 1-248 83
1-235
Chaperone/HSP
Bull 15660/
XP 001894589.1/
GI:170578901 DnaJ domain containing protein 85 11-839
80 1-839
Bm 1 22450/
XP 001895946.1/ hemimethylated DNA binding domain
GI:170582031 containing protein 97 29-119
91 28-119
DNA/RNA Binding
Bull 41070/
XP 001899675.1/ Zinc finger DHEIC domain containing
GI:170589828 protein 5, putative 90 28-445
88 1-445
Glycosylation/glucuronidation
Bml 34610/
XP 001898369.1/
GI:170587206
glycosyl transferase, group 2 family protein 89 1-435 88
1-582
Bull 44655/
XP 001900394.1/
GI:170591272 Fukutin.-related 85 1-364 75
1-364
oe
TABLE B (CONTINUED)
Bml 13480/
0
t.)
XP 001894161.1/ UDP-glucoronosyl and UDP-glucosyl
1¨,
GI:170577851 transferase family protein 81
1-423 72 155-502 c:
1¨,
.6.
Immunological
.6.
c:
Bml 50985/
=
XP 001901665.1/ Complement component C6 precursor.-
GI: 170593827 related 61
2-166 75 3-171
Miscellaneous
Bml 15480/
XP 001894556.1/
GI:170578816 Acyltransferase family protein 86
266-467 76 49-638
Bml 23850/
XP 001896227.1/
P
2
GI:170582654 cDNA sequence BC017158-related 82
1-389 72 21-389
c:
Bml 49590/
o ,D
XP 001901384.1/
,D
GI:170593263 CG3054-PA-related 63
1-262 67 1-254 ,
..,
,
Bml 15855/
.7
,
XP 001894628.1/
.
GI:170578992 D4Ertd196e protein, putative 86
1-177 81 1-151
Bm1 10500/
XP 001894628.1/
GI:170578992 AMOP domain containing protein 94
1-1513 90 609-1513
Bml 06760/
XP 001892822.1/
Iv
GI:170574457 zgc: 100814 protein-related 84
1-357 71 1-356 n
,-i
Bml 41280/
XP 001899713.1/ uncharacterized hypothalamus protein
cp
t.)
o
GI:170589904 HTMP, putative 81
1-296 80 1-296
c:
'a
t.)
t.)
--.1
oe
--.1
TABLE B (CONTINUED)
0
t.)
o
1-,
Bml 17180/
c:
1-,
XP 001894893.1/ MiaB-like tRNA modifying enzyme,
.6.
.6.
GI:170579583 archaeal-type family protein 94
1-390 95 1-265 c:
o
Bml 48010/
XP 001901064.1/
GI:170592623 EGF-like domain containing protein 74
6-556 64 6-546
Proteases
Bml 18805/
XP 001895218.1/ Papain family cysteine protease
GI:170580338 containing protein 56
134-313 41 1-314
Bml 38300/
P
XP 001899113.1/
2
-,'
GI:170588703 Peptidase family M1 containing protein
74 1-819 70 1-819
c:
.
1-, Bm1 26370/
.
r.,
XP 001896728.1/
,
..,
,
GI:170583765 Rhomboid family protein 83
1-377 85 17-377
,
Bml 11005/
,
XP 001896728.1/
GI:170583765 MGC84665 protein-related 91
1-98 90 1-40
Bml 53050/
XP 001902078.1/
GI:170594653 Reprolysin 79
1-839 77 1-843
Possible Protease
1-d
Binl 00205/
n
XP 001891567.1/
GI:170571016 ShTK domain containing protein 46
126-264 55 110-264 cp
t.)
o
Protease inhibitor
1-
c7,
'a
t.)
t.)
--4
oe
--4
TABLE B (CONTINUED)
Bm1 09775/
0
XP 001893428.1/
GI:170575897 serpin, putative 54 1-391
52 1-391
Sterol
Sterol Metabolism Metabolism
Bm1 37660/
XP 001898982.1/
GI:170588441 Oxysterol-binding protein 82 57-753
86 57-753
Structural Structural
BBm1 53475/
XP 001902163.1/ Nematode cuticle collagen N-terminal
GI:170594883 domain containing protein 64 1-281
55 46-291
Bm1 04695/
XP 001892417.1/
GI:170573305 Cuticle collagen F09G8.6.-related 89 1-270
86 1-269
Bm1 19730/
XP 001895401.1/
GI:170580769 Autophagy protein Apg9 containing protein 86 1-814
81 1-814
Transporters
Bm1 08720/
XP 001893214.1/
GI:170575377 ABC transporter N-terminus family protein 84 1-153
72 1-153
Bml 06830/
XP 001892835.1/ ABC transporter transmembrane region
GI:170574488 family protein 81 82-248
62 1-244
Bml 08185/
XP 001893108.1/
GI:170575121 Cation transporter family protein 57 32-345
59 67-345
oe
TABLE B (CONTINUED)
Bm1 34425/
0
XP 001898332.1/
GI:170587131 Ctr copper transporter family protein 74 2-276
73 1-276
Bm1 00795/
XP 001891680.1/
GI:170571314 E1-E2 ATPase family protein 91 45-531
85 1-529
Bm1 42365/
XP 001899937.1/
GI:170590354 ZIP Zinc transporter family protein 81 28-387
43 17-386
Bm1 40010/
XP 001899457.1/
GI:170589391 NRAMP-like transporter Kl1G12.4, putative 91 1-456
83 1-457
Bml 38955/
p
XP 001899244.1/ Twik family of potassium channels protein
GI:170588965 28, putative 92 1-561
91 1-561
Bm1 44770/
XP 001900417.1/ TWiK family of potassium channels protein
GI:170591318 7, putative 94 1-525
91 1-525
Bm1 24840/
XP 001896428.1/
GI:170583097 Major Facilitator Superfamily protein 87 1-418
86 1-493
Bml 37140/
XP 001898875.1/
GI:170588227 Major Facilitator Superfamily protein 75 1-738
71 1-739
Bm1 24985/
XP 001896457.1/
GI:170583158 cation efflux family protein 85 1-483
81 1-483
oe
TABLE B (CONTINUED)
Brill 46360/
0
XP 001900734.1/ Transmembrane amino acid transporter
GI:170591953 protein 86 1-443
91 1-439
Brill 25200/
XP 001896499.1/
GI:170583257 Mitochondria' carrier C16C10.1, putative 89 1-332
83 1-332
Brill 01695/
XP 001891855.1/
GI:170571765 RE11181p-related 26 4-105
23 4-258
Bml 42075/
XP 001899877.1/
GI:170590234 zgc:92765, putative 84 1-396
74 1-396
Bm 1 43555/ ABC TRANSPORTER
p
XP 001900172.1/ TRANSMEMBRANE REGION
GI:170590826 FAMILY PROTEIN 71 12-996
71 14-1423
Brill 37475/
XP 001898945.1/
GI:170588367 Major Facilitator Superfamily protein 82 1-792
78 113-795
Bm 1 38360/
XP 001899125.1/
GI:170588727 major facilitator superfamily protein 93 31-565
91 21-564
Brill 15490/
XP 001894558.1/
GI:170578824 ABC transporter family protein 89 4-713
77 7-638
Bm 1 31305/
XP 001897706.1/ vesicular acetylcholine transporter unc-
GI:170585872 17, putative 92 1-528
87 1-528
oe
TABLE B (CONTINUED)
Bm1 42930/
0
XP 001900048.1/ Excitatory amino acid transporter,
GI:170590576 putative 92 1-498
93 1-499
Bm1 02560/
XP 001892014.1/
GI:170572178 Sodium/calcium exchanger protein 79 1-342
71 1-314
Bml 31865/ Probable calcium-binding
XP 001897818.1/ mitochondria' carrier F55A11.4,
GI:170586099 putative 82 8-501
86 4-508
Hypothetical
Proteins
Binl 04935/
XP 001892465.1/
p
GI:170573424 hypothetical protein 72 1-111
66 1-112
Bm1 33605/
XP 001898167.1/
GI:170586800 hypothetical protein 58 111-216
22 19-188
Bm1 34095/
XP 001898267.1/
GI:170587000 hypothetical protein 81 1-131
71 1-129
Bml 22820/
XP 001896020.1/
GI:170582194/ hypothetical protein 98 1-81 96
1-81
Bml 26845/
XP 001896819.1/
GI:170584006 Hypothetical protein 81 63-162
72 1-245 1-d
TABLE B (CONTINUED)
Bm1 45625/
0
i..)
XP 001900588.1/
1¨
GI:170591660 hypothetical protein 82
1-332 76 1-332 o
1¨
.6.
Bml 52210/
o
.6.
XP 001901910.1/
o
o
GI:170594317 hypothetical protein 87
15-432 84 1-430
Bm1_02860 hypothetical protein 33
11-31 33 11-31
Bml 57335/
XP 001902925.1/
GI:170596866/ Conserved hypothetical protein, putative 91
1-246 87 1-246
Bm1 25895/
XP 001896638.1/
GI:170583561 hypothetical protein 74
31-325 67 24-325 p
Bm1 26820/
2
XP 001896814.1/
.3
o .
o GI:170583994
hypothetical protein 77 1-317 72 99-317
o
r.,
Bm1 46300/
,
_.]
XP 001900722.1/
'
GI:170591929 hypothetical protein, conserved 75
1-191 56 18-380 ,
,
Bml 20460/
XP 001895546.1/
GI:170581122 hypothetical protein 86
1-191 85 1-191
Bm1 27875/
XP 001897026.1/
GI:170584478 hypothetical protein 79
12-202 77 185-298
Bm1 30935/
1-d
n
XP 001897629.1/
GI:170585718 hypothetical protein 64
9-90 28 17-70
cp
Bm1 53700/
i..)
o
1¨
XP 001902205.1/
7:-:--,
GI:170594994 hypothetical protein 57
53-236 62 2-103 i..)
i..)
--.1
oe
--.1
TABLE B (CONTINUED)
Bm1 57235/
0
XP 001902905.1/
GI:170596815 hypothetical protein 85 10-67 74
1-68
Bml 45100/
XP 001900482.1/
GI:170591448 hypothetical protein 67 81-696
49 271-727
Bm1 07875/
XP 001893045.1/ CONSERVED HYPOTHETICAL
GI:170574981 PROTEIN 90 42-231 90 41-231
Bml 30410/
XP 001897520.1/
GI:170585498 conserved hypothetical protein 90 1-234 94
154-234
Bml 17550/
XP 001894967.1/
GI:170579749 hypothetical protein 77 77-129
86 82-125
Bm1 00920/
XP 001891702.1/ Hypothetical 30.5 kDa protein ZK1321.3 in
GI:170571368 chromosome II.-related 75 1-174 75
1-176
Bm1 04875/
XP 001892453.1/
GI:170573392 hypothetical protein xx xx xx
xx
Bm1 29435/
XP 001897329.1/
GI:170585108 Hypothetical protein 89 23-204
81 23-204
Bml 42465/
XP 001899956.1/
1-d
GI:170590392 hypothetical protein 25 14-387
25 14-385
oe
TABLE B (CONTINUED)
Bm1 48705/
0
XP 001901204.1/
GI:170592903 conserved hypothetical protein 81
1-268 72 1-269
Bml 32415/
XP 001897928.1/ Hypothetical 21.5 kDa protein in SEC15-
GI:170586322 SAP4 intergenic region.-related 93
1-176 91 1-176
Bml 07845/
XP 001893039.1/
GI:170574965 hypothetical protein 75
1-210 72 60-210
Bml 15300/
XP 001894520.1/
GI:170578730 Hypothetical protein xx
xx xx xx
Bm1 17255/
XP 001894908.1/
GI:170579615 hypothetical protein 73
13-251 75 28-251
oe Bm1 18965/
XP 001895250.1/
GI:170580404 Hypothetical protein 85
1-236 77 1-239
Bm1 20325/
XP 001895519.1/
GI:170581054 Hypothetical protein-conserved 91
1-487 89 1-485
Bm1 44010/
XP 001900264.1/
GI:170591010 hypothetical protein 72
9-185 32 61-129
Bm1 46230/
XP 001900708.1/
1-d
GI:170591901 hypothetical protein 65
18-278 31 161-281
oe
TABLE C
SELECTED PROTEINS FROM TABLES A AND B CONTAINING 1-2 TRANSMEMBRANE DOMAINS, A
SIGNIFICANT NON- 0
tµ.)
CYTOPLASMIC PORTION, >75% HOMOLOGY TO EITHER W. BANCROFTI OR 0. VOLVULUS AND
<40% HOMOLOGY TO HUMANS. o
1¨.
o
1¨.
.6.
SEQ ID NO:/ H. sapiens W. bancrofti 0. volvulus
L. loa D. immitis
.6.
Gene Symbol
o
o
%Ident* Query %Ident* Query %Ident* Query
%Ident* Query %Ident* Query
cov**. Cov** Cov**
Cov** Cov**
1/ Bm 1 39630/ 28 45-1170 97 628- 87 26-1171 89
1-1171 82 1-1171
XP 001899381.1/ 1171
GI:170589239
2/ 35 53-206 96 1-269 82 3-269 89
62-269 79 2-269
Bm1 02820/
p
XP 001892066.1/
2
GI:170572325
.3'
.
r.,
3/ 24 212-281 95 10-281 79 10-281 83
10-281 84 10-281 ,2
..,
Bml 30585/
,
XP 001897556.1/
,
,
GI:170585572
4/ 34 15-1280 98 1-681 92 1-1280 95
1-1280 93 1-1280
Bm1 19395/
XP 001895334.1/
GI:170580602
5/ 40 22-287 95 9-293 79 2-293 88
9-293 79 1-290 Iv
n
Bml 38285/
XP 001899110.1/
cp
GI:170588697
t.)
o
1¨,
c:
'a
*%Ident" is the percentage of amino acids within the query coverage identical
to query sequence. t.)
t.)
**Query coy." span of amino acids in the query sequence that aligns with the
target sequence producing significant alignment --.1
oe
--.1
TABLE C (CONTINUED)
6/ 27 25-835 91 1-839 77 3-839
85 11-839 80 1-839 0
r..)
Brill 15660/
1¨,
cA
XP 001894589.1/
.6.
GI:170578901
.6.
cA
o
7/ 25 34-112 97 29-119 95 29-119
97 29-119 91 28-119
Brill 22450/
XP 001895946.1/
GI:170582031
8/ 31 138-364 96 1-362 73 1-364
85 1-364 75 1-364
Brill 44655/
XP 001900394.1/
GI:170591272
P
,30
9/ 27 35-509 95 1-425 29 214-293
81 1-423 72 155-502 ..,'
.3'
-4
o Bml 13480/
r.,
XP 001894161.1/
,9
GI:170577851
,
..'-'
10/ 28 97-260 81 1-242 69 1-260
63 1-262 67 1-254
Brill 49590/
XP 001901384.1/
GI:170593263
11/ 26 652-932 98 679- 92 1-1513
94 1-1513 90 609-1513
Brill 10500/ 1377
XP 001893572.1/
Iv
GI:170576299/
n
,-i
cp
w
=
cA
-a-,
w
w
coi
-4
TABLE C (CONTINUED)
12/ 36 10-395 91 19-338 66 6-560
74 6-556 64 6-546 0
r..)
Bml 48010/
1-,
cA
XP 001901064.1
.6.
GI:170592623/
.6.
cA
o
13/ 28 136-586 90 90-819 67 1-819
74 1-819 70 1-819
Bml 38300/
XP 001899113.1/
GI:170588703
14/ 38 2-98 95 1-96 80 1-98
91 1-98 90 1-40
Bml 11005/
XP 001893672.1/
P
GI:170576544
2
`.. ,
.3'
-4
1-, 15/ 32 153-753 91 96-845 77 1-839
79 1-839 77 1-843
r.,
Bml 53050/
,2
XP 001902078.1/
GI:170594653
,
..'-'
16/ 27 54-161 80 142-229 52 70-227
46 126-264 55 110-264
Bm1 00205/
XP 001891567.1/
GI:170571016
17/ 29 26-388 75 84-375 52 29-390
54 1-391 52 1-391 Iv
Bm1 09775/
n
1-i
XP 001893428.1/
cp
GI:170575897
r..)
o
1-,
cA
'a
r..)
n.)
coi
-4
TABLE C (CONTINUED)
18/ 29 238-350 97 53-433 85 1-431
87 15-432 84 1-430 0
r..)
Bml 52210/
1-,
cA
XP 001901910.1/
.6.
GI:170594317
.6.
cA
o
19/ 31 114-236 96 1-246 89 1-246
91 1-246 87 1-246
Bml 57335/
XP 001902925.1/
GI:170596866
20/ 30 103-147 24 94-147 82 1-191
86 1-191 85 1-191
Bm1 20460/
XP 001895546.1/
P
GI:170581122
2
`.. ,
.3'
ri 21/ 29 330-414 85 118-727 60 75-727
67 81-696 49 271-727
r.,
Bml 45100/
,2
XP 001900482.1/
GI:170591448
,
..'-'
22/ 31 84-225 99 142-231 85 53-231
90 42-231 90 41-231
Bm1 07875/
XP 001893045.1/
GI:170574981
23/ 33 63-121 87 77-129 82 82-125
77 77-129 86 82-125 Iv
Bml 17550/
n
1-i
XP 001894967.1/
cp
GI:170579749
r..)
o
1-,
cA
'a
r..)
n.)
coi
-4
TABLE C (CONTINUED)
24/ 28 24-108 89 1-210 64 1-210
75 1-210 72 60-210 0
r..)
Bm1 07845/
1¨,
cA
XP 001893039.1/
.6.
GI:170574965
.6.
cA
o
25/ 21 93-246 87 17-251 78 28-251
73 13-251 75 28-251
Bm1 17255/
XP 001894908.1/
GI:170579615
26/ 37 2-215 96 1-487 89 1-487
91 1-487 89 1-485
Bm1 20325/
XP 001895519.1/
P
GI:170581054
2
f,
.3'
d 27/ 29 184-256 91 24-278 62 1-278
65 18-278 31 161-281
r.,
Bm1 46230/
,2
XP 001900708.1/
GI:170591901
,
..'-'
Iv
n
,-i
cp
w
=
cA
-c-:--,
w
w
coi
-4
TABLE D
NORMALIZED SPECTRAL ABUNDANCE FACTOR (NSAF) AND NSAF ENRICHMENT
0
tµ.)
SEQ ID NO. NSAF enrichment* NSAF
Abundance**
Intestine Body Wall Reproductive Intestine
Non-cytoplasmic Transmembrane
Tract
domain' (TMHMM)b
1/ Bml 39630/ 3.84 0.26 0 2.20E-05
19-1120 1
XP 001899381.1/
GI:170589239
2/ 9999 0 0 1.30E-04
1-225 1
Bml 02820/
XP 001892066.1/
GI:170572325
3/ 4.42 0 0.23 8.40E-05
19-135 1
Bm 1 30585/
XP 001897556.1/
GI:170585572
4/ 3.42 0.14 0.12 3.30E-05
1-942 1
Bull 19395/
XP 001895334.1/
GI:170580602
5/ 7.68 0.13 0 1.80E-04
41-293 1
Bm 1 38285/
XP 001899110.1/
GI:170588697
*Calculated as described in the Examples
**Calculated as described in the Examples
a Non-cytoplasmic domain refers to the span of amino acids predicted to be non-
cytoplasmic as described in the Examples
oe
b Transmembrane refers to number of transmembrane domains as predicted by a
membrane protein topology prediction method TMHMINI as described in the
Examples.
TABLE D (CONTINUED)
0
6/ 10.31 0 0.1 7.20E-05
18-220 1
Bail 15660/
XP 001894589.1/
GI:170578901
7/ 2.74 0.17 0.14 2.70E-04 1-
125 1
Bm1 22450/
XP 001895946.1/
GI:170582031
8/ 2.95 0 0.34 4.70E-05
28-364 1
Bm1 44655/
XP 001900394.1/
GI:170591272
9/ 28.16 0.04 0 7.40E-04 1-
486 1
Bm 1 13480/
XP 001894161.1/
GI:170577851
10/ 2.95 0 0.34 6.50E-05 1-
51, 101-265 2
Bm1 49590/
XP 001901384.1/
GI:170593263
11/ 5.99 0.01 0.15 6.10E-04
23-1322 1
Bail 10500/
XP 001893572.1/
GI:170576299/
coi
TABLE D (CONTINUED)
12/ 2.03 0.38 0.06 2.50E-04 1-
430 1 0
Bm 1 48010/
XP 001901064.1
GI:170592623/
13/ 9999 0 0 1.60E-05
81-1061 1
Bm 1 38300/
XP 001899113.1/
GI:170588703
14/ 2.74 0.17 0.14 2.00E-04 1-
16,76-169 1
Bm 1 11005/
XP 001893672.1/
p
GI:170576544
15/ 2.95 0 0.34 6.10E-04 1-
607 1
Bm 1 53050/
XP 001902078.1/
GI:170594653
16/ 3.42 0.23 0.04 4.200+00
26-264 1
Bm1 00205/
XP 001891567.1/
GI:170571016
17/ 2.56 0.39 0 4.70E-05
17-391 1
Bail 09775/
XP 001893428.1/
GI:170575897
coi
TABLE D (CONTINUED)
18/ 9999 0 0 4.00E-05 1-
369 1
Bm 1 52210/
0
XP 001901910.1/
GI:170594317
19/ 9999 0 0 7.00E-05
29-211 2
Bm 1 57335/
XP 001902925.1/
GI:170596866
20/ 2.95 0 0.34 8.00E-05
143-147 2
Bm1 20460/
XP 001895546.1/
GI:170581122
p
,õ0
21/ 5.12 0.2 0 4.70E-05
285-727 1
Bm 1 45100/
XP 001900482.1/
GI:170591448
22/ 4.42 0 0.23 1.10E-04 1-
56. 1
Bail 07875/
XP 001893045.1/
GI:170574981
23/ 2.56 0.39 0 1.30E-04 1-
61. 1
Bm 1 17550/
XP 001894967.1/
GI:170579749
coi
TABLE D (CONTINUED)
24/ 2.09 0.15 0.24 4.90E-04
53-210 1
Brill 07845/
0
XP 001893039.1/
GI:170574965
25/ 3.64 0.2 0.05 3.80E-04
36-251 1
Brill 17255/
XP 001894908.1/
GI:170579615
26/ 3.36 0.12 0.14 3.00E-04
1-194 1
Bm1 20325/
XP 001895519.1/
GI:170581054
p
,õ0
27/ 2.21 0 0.45 1.80E-04
121-289 1
oe Brill 46230/
XP 001900708.1/
GI:170591901
coi
